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Abstract: Wnt signalling regulates several cellular functions including proliferation, differentiation,
apoptosis and migration, and is critical for embryonic development. Stem cells are defined by their
ability for self-renewal and the ability to be able to give rise to differentiated progeny. Consequently,
they are essential for the homeostasis of many organs including the gastrointestinal tract. This review
will describe the huge advances in our understanding of how stem cell functions in the gastrointestinal
tract are regulated by Wnt signalling, including how deregulated Wnt signalling can hijack these
functions to transform cells and lead to cancer.
Keywords: stem cells; Wnt signalling; epithelium; cancer; regeneration; plasticity; intestine;
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1. Introduction
1.1. Adult Stem Cells
Adult stem cells play a vital role in multicellular organisms by maintaining normal tissue
homeostasis by ensuring sufficient cells are produced to populate the tissue [1]. They constitute
a small population of cells that are defined as having the capacity of both long-term self-renewal and
the ability to give rise to at least one type of differentiated cell [2]. Numerous types of precursor cells
have been isolated in adult tissues, leading to the concept that organs contain a population, or several
populations, of resident stem cells to maintain tissue homeostasis [3].
Prevailing models assume the existence of a single quiescent population of stem cell residing in
a niche, however, recent evidence [4] demonstrates the existence of long-lived yet actively cycling stem
cell populations. This suggests that clusters of quiescent and active adult stem cells may cohabit the
same tissue so that the demands of tissue maintenance and repair can be shared between populations,
rather than heaping all cellular responsibilities on a single population [5]. Recent discoveries in the
gastrointestinal (GI) tract suggest a model of co-operative stem cell hierarchy whereby proliferative
stem cells meet the day-to-day requirements of the tissue and quiescent ‘reserve’ stem cells facilitate
tissue regeneration following cytotoxic damage [6].
Several populations of adult stem cells have been identified as the cell of origin for cancer [7].
Stem cells self-renew and have the capacity to promote regeneration, a process similar to
tumourigenesis, and therefore it is not surprising that oncogenes, or loss of tumour suppressor
Genes 2018, 9, 178; doi:10.3390/genes9040178 www.mdpi.com/journal/genes
Genes 2018, 9, 178 2 of 32
genes, are able to hijack these functions to transform these cells [8,9]. Therefore, identification of these
cells is also important to help fully understand cancer biology, as well as normal tissue functions.
Although the function of stem cells, and how they are regulated is not fully understood, the past
15 years has revealed many of the complex signalling events controlling stem cells and identified
a critical interaction between stem cells and the microenvironment, or niche, in which they reside.
A stem cell niche is composed of other cell types including epithelial and stromal cells, signalling
factors and extracellular matrix, which in combination with stem cells intrinsic characteristics, defines
their properties and potential [10].
The GI tract is a challenging environment for its cellular constituents, most notably the epithelium,
which is at the frontline of harsh luminal contents and mechanical stress. Fundamental to prolonged
survival, the GI epithelium has evolved the capacity to remove any exhausted cells and replenish
the epithelium with spritely participants. Importantly, GI epithelial renewal is powered by resident
stem cells, which depend on the coordinated effort of various cellular and biochemical components.
This review will focus on the remarkable progress made over the past 15 years in which Wnt signalling
has emerged as one of the critical signalling pathways regulating GI tract stem cells. Although the
oesophagus is also part of the GI tract, the identification and function of stem cells in this organ has
yet to be fully established with the same level of detail as in the stomach and intestine and thus is not
covered in this review [11,12].
1.2. Wnt Signalling
Wnt signalling can regulate several cellular functions, including proliferation, differentiation,
migration, apoptosis and migration [13]. As such, it is critical during embryonic development, and regulates
homeostasis and stem cell function in several adult tissues including the intestine [14–17], stomach [18],
breast [19] and liver [20] (Table 1). The first Wnt gene, Wnt1 (originally named Int-1), was identified in
1982 by Nusse and Varmus who described the cloning of a new murine proto-oncogene [21]. It was
then observed that its fruit fly homolog was wingless (Wg), a gene essential in segment polarity during
embryonic development [22]. Further investigation since has shown that Wnt1 belongs to a family of
highly conserved genes known as the wingless-type mouse mammary tumour virus (MMTV) integration
site (Wnt) gene family. There are currently 19 known Wnt genes in the genomes of mice and humans [23],
which transmit signals via three different pathways; the canonical Wnt pathway, the non-canonical planar
cell polarity pathway, and the non-canonical Wnt/calcium pathway [24]. Although distinct, there is
considerable cross-talk between each Wnt pathway, and thus Wnt signalling can be considered more
broadly as a signalling network containing distinct arms.
Table 1. The effects of Wnt ligands on gastrointestinal stem cell populations during homeostasis
and cancer.
Gene Expression Homeostasis Cancer Reference
WNT1 Gastric epithelium
Gastric stem cell
maintenance.
Regulates Oct4.
Overexpressed in GC. [25]
WNT2 Gastric epithelium Unknown. Overexpressed in GC and CRC.Promotes cell reprogramming. [26]
WNT2B Gastric gland base,intestinal stroma
Unknown, Intestinal stem
cell maintenance. Over expressed in CRC and GC. [27–29]
WNT3A Paneth cell/crypt Intestinal stemcell maintenance. Over expressed in CRC and GC. [28,30]
WNT4
Gastric isthmus,
intestinal
mesenchyme/epithelium
Unknown, intestinal crypt
maintenance/regeneration. Increased expression in GC. [27,29]
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Table 1. Cont.
Gene Expression Homeostasis Cancer Reference
WNT5A Corpus stroma, intestinalvilli, colonic epithelium
Gastric stem cell niche,
colonic regeneration.
Promotes invasion and prevents
anoikis in GC. [31–33]
WNT6 Paneth cell/crypt,gastric gland
Intestinal stem cell
maintenance, supports
gastric niche.
Over expressed in GC. [29,33,34]
WNT9A Gastric isthmus and base Unknown. Over expressed in CRC and GC. [29,35]
WNT9B Paneth cell/cryptgastric isthmus
Intestinal stem cell
maintenance, unknown. Unknown. [29,33]
WNT10B Gastric epithelium Unknown. Required for proliferation andmigration in GC. [29,36]
WNT11 Gastric isthmus, surfacepit and neck Unknown. Increased expression in CRC. [29,37]
WNT16B Gastric epithelium Unknown. Overexpressed in GC. [38]
Wnt ligands are secreted glycoproteins that activate signalling pathways through the interaction
with a cell surface receptor of the frizzled (FZD) family [39,40]. There are 10 FZD genes in mammals,
which can form complexes with other FZD proteins and associate with co-receptors such as low-density
lipoprotein-related protein (LRP), most commonly LRP5/6, ROR2 or Ryk to transmit signalling into
the cell [41,42]. In the canonical pathways, the absence of Wnt ligands leads to the phosphorylation
of β-catenin by the destruction complex, which contains the scaffold protein Axin, APC, GSK3β and
CK1-alpha. The phosphorylated β-catenin is targeted for proteasomal degradation. This absence of
nuclear β-catenin initiates a complex of TCF/LEF and Groucho to recruit HDACs to repress target
genes. Upon binding of Wnt to FZD and LRP co-receptors, the LRP receptors are phosphorylated
by CK1-alpha and GSK3β [43] which recruit disheveled (DVL) and axin proteins to the plasma
membrane where they become polymerized and activated [44]. The DVL polymers inactivate the
destruction complex resulting in the stabilization and accumulation of β-catenin, which translocates
to the nucleus [45]. Once in the nucleus, β-catenin forms an active complex with lymphoid enhancer
factor (LEF) and T-cell factor (TCF) proteins by disarming TLE/Groucho repression and recruiting
histone modifying co-activators, such as Pygo and bcl9 [46] to initiate target gene transcription.
Wnt signalling that is independent of β-catenin is referred to as the non-canonical pathway where
a transcriptional response is elicited via an alternative mode of downstream signalling not involving
β-catenin–TCF or β-catenin-LEF [24]. There is currently a myriad of non-canonical Wnt pathways
which are classified based on the configuration of FZDs and co-receptors involved as well as their
downstream effects, however they can be broadly categorized into two pathways; the planar cell
polarity (PCP) pathway and the Wnt/Calcium (Wnt/Ca2+) pathway.
The PCP pathway was originally identified in Drosphila when phenotypes to hairs, bristles and
ommatidia were observed in mutants including Fzd, Dsh, Celsr, Vangl and Prickle. These genes code
for proteins that transmit PCP signalling to regulate cell polarity within the plane of the epithelial
sheet making the PCP pathway vital for many developmental processes [47,48]. This pathway is
activated when Wnt5a, Wnt7a, Wnt8b or Wnt11 bind to FZD receptors and their respective receptor
tyrosine kinases; Ror2 or Ryk [49]. This variety of Wnt ligand, FZD receptors and co-receptors allows
for significant variation in the transmission of the signal and depending on which complex is activated
determines which cytoplasmic PCP pathway signal transduction components are activated such as
c-JUN N-terminal Kinase, DVL, Cdc42, RhoA and Rac1 [50]. PCP signalling is also activated when
Fzd7 associates with Syndican4 (Sdc4) and R-Spondin (R-Spo) which transmits Wnt5a signals via the
internalization of the whole receptor/ligand complex [51–53]. Recent data has indicated that PCP
signalling may also promote proliferation in an assortment of different cancers [54–58].
The Wnt/Ca2+ pathway was first identified in zebrafish embryos where over-expression of Wnt5a
was observed to increase the frequency of Ca2+ signalling [59] and activate protein kinase C (PKC)
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and calcium/calmodulin-dependent protein kinase in Xenopus [60]. Wnt/Ca2+ signalling is initiated
by the interaction of the Wnt/Fzd receptor complex along with the participating co-receptor Ror1/2
which leads to the production of inositol 1,4,5-triphosphate (IP3) and 1,2-diacylglycerol (DAG) as well
as calcium via the action of membrane-bound enzyme phospholipase C (PLC). The PLC modifies
IP3 and DAG which allows IP3 to diffuse through the cytosol and interact with the calcium channels
on the endoplasmic reticulum which results in the efflux of calcium ions; DAG and the intracellular
calcium activate PKC. In conjunction with calmodulin, calcium also activates calmodulin dependent
protein kinase II (CaMKII). PKC and CaMKII activate numerous regulatory proteins, such as CREB
and NFκB, which regulate target gene expression [61].
The formation of Wnt/Fzd/Lrp6 signalling complexes has traditionally been viewed to transduce
a linear signal transduction cascade, which centres around stabilization of β-catenin, colloquially
known as canonical Wnt signalling. However, recent elegant work from Christof Niehrs and colleagues
has shown this pathway has the capacity to bifurcate at the level of Wnt/Lrp6 to initiate other cellular
processes independent of β-catenin [62]. For example, Wnt/Lrp6 signalling can sequester up to 70% of
the cellular pool of GSK3 in multivesicular bodies, which prevents the many targets of GSK3-mediated
phosphorylation being ubiquitylated and degraded [63]. As such, Wnt-dependent stabilization of
proteins (Wnt/STOP) peaks during mitosis to slow protein degradation as cells prepare to divide,
which influences not only cell-cycle progression but cytoskeletal dynamics, endolysosomal biogenesis
and DNA remodelling [62].
The decision of which pathway will be engaged is dependent on the availability of co-receptors
and Wnt ligands, thus providing huge complexity and redundancy in the system. As such, there is
considerable overlap between the Wnt pathways, for example, Wnt5a/Ca2+ signalling can negatively
regulate the canonical Wnt signalling pathway [64,65] however, in other contexts Wnt5a is able to
activate β-catenin-dependent transcription in the presence of Fzd4 [66]. In addition, Wnt5a can work
in co-operation with the Ror2 receptor to promote β-catenin degradation independently of GSK3 and
therefore inhibit Wnt3a-medicated canonical Wnt signalling [67,68].
Despite there being extensive knowledge surrounding canonical Wnt signalling in the GI tract,
both in normal homeostasis and cancer, the function of non-canonical Wnt signalling has been less
well characterised; this is in part due to the lack of suitable reagents and robust assays. Having said
that, Wnt5a, a classical non-canonical Wnt, is critical for mucosal healing and regeneration in the
colon following injury. Wnt5a plays an instructive role via potentiating TGFβ signalling to limit the
proliferation of intestinal stem cells (ISCs) at the site of injury [31], which highlights the multiplexed
control of ISCs by Wnt signalling. Non-canonical Wnt signalling is also involved with migration
mediated via Fzd7 [69] as well as being critical for the survival, invasion and metastatic capabilities
of colon cancer cells [70]. However, the exact relation of Fzd7 with non-canonical signals in CRC is
unknown. Although it is well documented that Wnt5a is overexpressed in both CRC [71] and GC [32]
the precise mechanisms of the non-canonical pathways involvement are less well understood. It has
been shown that compared to normal tissue, ROR2 is frequently downregulated in gastric carcinoma
tissues, which suggests that ROR2 has a tumour suppressive role in gastric carcinoma [72]. The exact
underlying mechanisms by which ROR2 acts and how the canonical and non-canonical pathways
interact requires further investigation.
2. Intestinal Stem Cells and Wnt Signalling
2.1. Biology of the Intestinal Epithelium
The epithelial lining of the intestine allows efficient exchange and absorption of nutrients whilst
simultaneously excluding passage of harmful molecules and organisms, and undergoing constant
renewal [73]. For these reasons the intestinal epithelium represents an excellent model to study the
processes that regulate cell renewal, differentiation and homeostasis. The bulk of the simple columnar
epithelium of the small intestine is composed of finger-like projections known as villi that extend into
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the intestinal lumen and house the various cell types needed for nutrient exchange and absorption [74].
At the bases of villi are mucosal invaginations, the crypts of Lieberkühn, (referred from herein as crypts)
which are home to progenitor cells, differentiated Paneth cells and ISCs (Figure 1). The colon lacks
villi, but still retains the crypt-like structures, which house the stem cells, located in the base, and the
differentiated progeny [75]. The colon absorbs water, including water with ions, vitamins and nutrients
dissolved in it from host gut bacteria in all the differentiated cells. Variable chemical, biological
and mechanical stresses encountered by the intestinal epithelium stimulate a perineal renewal along
a vertical (crypt-villus) intestinal axis every four to five days, which serves as a protective mechanism to
rid the epithelium of any cells that have undergone genotoxic insult. The driving force behind epithelial
renewal of the intestine are ISCs that proliferate daily [4,76] to generate a population of unspecified
transit-amplifying (TA) cells that rapidly divide while migrating vertically along an epithelial conveyer
belt to produce new secretory, enteroendocrine and absorptive lineages that replenish exhausted cells
at the villus tips (or top of the crypt in the colon), which undergo apoptosis and are shed into the
lumen. However, secretory Paneth cells in the small intestine, or cKit+/Reg4+ cells in the colon [77,78],
do not follow the rapid renewal and migration pattern displayed by other intestinal cell types; Paneth
cells are renewed every 3-6 weeks by committed secretory progenitor cells located at the base of the
TA compartment, which mature into fully differentiated Paneth cells as they migrate toward the crypt
base. Paneth cells play important roles in controlling the ISC microenvironment through secretion of
antimicrobial peptides (defensins and lysozyme) and various growth factors that confer ‘stemness’
(Wnt, EGF and Notch) [79,80]. Of these factors, extensive research demonstrates Wnt signalling as
a critical regulator of ISC maintenance. However, when Wnt signalling is deregulated it can provide
favourable conditions to transform cells [13].
Figure 1. Stem cell populations and signalling gradients of the gastrointestinal epithelium.
Schematic of the small intestinal epithelium depicting the various cell types, stem cell populations and
signalling gradients.
2.2. A Brief Perspective of Wnt Signalling in the Intestine
To understand why Wnt signalling plays such an instrumental role in ISC biology, we need to
understand how and why Wnt appeared on the radar of gastrointestinal researchers. Near the turn of
the 20th century, several groups mapped and functionally linked APC (previously discussed), located
on chromosome 5q21, to sporadic colorectal cancer (CRC) and familial adenomatous polyposis (FAP),
the latter being an autosomal dominant condition that drives the formation of hundreds to thousands
of small benign tumours in the large intestine, which can progress to cancer [81,82]. Following these
discoveries, immunoprecipitation experiments reveal complexes of APC bound to β-catenin [83],
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suggesting a role for APC in Wnt signal regulation. Importantly, seminal work published back-to-back
in Science show APC mutant colorectal cancers fail to regulate β-catenin, which permit constitutive
transcriptional activation of a β-catenin/TCF-4 complex, thus driving Wnt signalling in colorectal
cancer tissue [84,85]. However, until this point, the requirement of Wnt signalling in the normal
intestinal epithelium had not been tested. In the normal intestine, the role of Tcf-4 (encoded by Tcf7l2)
was elucidated by Korinek et al., which reveal neonatal Tcf7l2−/−mice exhibit a complete absence
of the prospective intestinal crypt and stem cell compartments leading to death shortly after birth,
highlighting for the first time the necessity of Wnt signalling for intestinal homeostasis and stem cell
maintenance [16]. These critical findings were soon reinforced by several key studies that embraced the
Cre-LoxP system [86] to permit the investigation of Wnt signalling in the adult intestinal epithelium,
which collectively demonstrate that manipulation of key regulators of the Wnt pathway impose an
aberrant Wnt-signal gradient, which significantly disrupts intestinal crypt-villus architecture and
homeostasis. In addition, FAP patients, in which one allele of APC is mutated and Wnt signalling
activated when the second is lost via loss-of-heterozygosity, present with polyps in the stomach as
well as the intestine, illustrating a role for Wnt in the regulation of gastric stem cells as well [87].
Together these highlight the importance of Wnt signalling for regulating stem cell function in the GI
tract, which is the focus of this review [88–92].
2.3. Identification and Dynamics of Intestinal Stem Cells
Two prevailing models of ISC identity have competed for legitimacy over the past four decades.
The identification of slender, undifferentiated, mitotically active crypt base columnar cells (CBCs)
provides the foundation for the “stem cell zone model”. Cheng and Leblond observed the gradual
presence of radiolabelled phagosomes, initially detected only in CBCs, in multiple cell lineages.
However, the various labelled cell types were observed in separate crypts, negating multipotency of
CBCs [93]. Additional evidence in support of CBC stemness came decades later through chemical
mutagenesis of the Dlb-1 locus, which generates long-lived clones comprised of all four intestinal
cell lineages. This was interpreted as evidence for CBC cells being self-renewing multipotent stem
cells [94]. In contrast, studies from Christopher Potten’s group propose cells positioned directly above
the uppermost Paneth cell, between +2 and +7, average of +4, relative to the crypt base embody
ISCs [76]. Potten’s +4 cells actively divide (daily), but can retain DNA incorporated labels, a trait
normally synonymous with cellular quiescence [95]. Moreover, the ability of +4 cells to retain DNA
labels while actively proliferating is thought to occur through selective segregation of old (labelled)
and new (unlabelled) DNA strands into stem cells and their daughter progeny, respectively, which was
proposed as a mechanism to reduce accumulation of DNA damage in long-lived stem cells [96,97].
Furthermore, the radiosensitivity of +4 cells is seen to be a desirable quality for stem cells as it
would prevent the accumulation of DNA replication errors that could be inherited by daughter
cells. Despite the recent discovery of specific markers for both candidate stem cell populations,
demonstrating which of the two models is correct has been immensely complex [73]. However, only
recently has a unifying theory that incorporates aspects of both models started to emerge and how
each stem cell pool contributes to intestinal homeostasis and regeneration (discussed below).
2.4. Markers of CBCs
While it was known that the cellular source of intestinal renewal resided within the crypts,
the precise identity of ISCs remained elusive until the beginning of the 21st century. In a landmark
study, Barker et al. confirmed a previously identified Wnt target gene, Lgr5 [92,98], to mark
a population of CBCs, which were decades earlier postulated to represent ISCs [93]. Each intestinal
crypt harbours approximately 14 Lgr5+ cells, some 10% of which occupy the +4 position,
which intercalate between Paneth cells. The generation of a Lgr5-EGFP-IRES-CreERT2 mouse was
used to demonstrate via lineage tracing that mitotically active Lgr5+ cells are self-renewing, long-lived
and multipotent [4]. Detailed investigations of the endogenous population dynamics of Lgr5+ cells
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using the Confetti reporter mouse and mathematical modelling reveal Lgr5+ cells drift towards
clonality and divide symmetrically, implying functional equivalence within the Lgr5+ ISC pool [99].
Intra-vital imaging further refines this model, showing ISCs compete for access to essential niche
factors (Wnt, EGF, Notch) at the crypt base, resulting in central ISCs having a survival advantage over
spatially displaced counterparts (border cells), which will maintain stemness and adopt a progenitor
fate respectively [100]. Furthermore, as Lgr5+ cells from the Lgr5-EGFP-IRES-CreERT2 knock-in
mouse express GFP, FACS isolated Lgr5GFP+ cells can generate three-dimensional self-renewing
ex vivo organoid cultures, complete with a full repertoire of intestinal lineages in the correct ratios
and anatomical position, thus providing additional evidence of Lgr5 as a marker of ISCs [80,101].
Subsequent investigations have shown Lgr5 marks stem cell populations in many other tissues
such as the hair follicle [102], stomach [103], ovary [104], kidney [105], liver [106], mammary [107],
pancreas [108], inner ear [109] and taste buds [110].
The utility of Lgr5 as a marker of ISCs has allowed multiple aspects of ISC biology to be better
understood, such as the molecular regulators of stem cell identity. Gene and proteomic signatures
of Lgr5+ ISCs [111] identify the transcription factor achaete scute-like 2 (Ascl2) as a master regulator
of ISCs, which co-operate with Tcf-4 and β-catenin to establish a Wnt-driven stem cell program at
the crypt base [111,112]. Like Lgr5, Ascl2 specifically marks CBCs and transgenic overexpression or
conditional deletion of Ascl2 result in crypt hypertrophy and rapid stem cell death respectively [113].
However, in the latter scenario, no gross intestinal phenotype is observed due to ‘escaper’ crypts
that can replenish the ISC pool [113]. Intriguingly, although Ascl2 can increase the number of ISCs
and its expression is positively correlated with CRC progression [114], forced expression of Ascl2 in
a mouse model of colon cancer doesn’t accelerate tumourigenesis, which suggests ectopic expression
in cells that do not normally express Ascl2, rather than overexpression, explain the aetiology of Ascl2
in CRC [115].
The ephrin family of signalling molecules regulate cell-position cues in a wide variety of tissues,
including the intestinal crypt-villus axis. Interactions between Eph receptors and ephrin ligands usually
facilitate cell repulsion [116] and within the crypt, Wnt signalling inversely regulates the expression of
EphB receptors and ephrinB ligands, creating correct compartmentalisation of undifferentiated and
differentiated cells [92]. Indeed, EphB3 is enriched in Lgr5+ cells and EphB2 is expressed uniformly
throughout the crypt, whereas the ephrinB1 and B2 ligands are expressed in the villi. Deletion of
EphB2 and EphB3 triggers a mislocalisation of Paneth cells combined with an abnormal intermingling
of proliferative and differentiated cells [117]. Furthermore, paralleling the results in normal crypts,
the graded expression of EphB2 in CRCs identifies tumour cell populations displaying ISC-like or
differentiated-like phenotypes [118].
2.5. Markers of +4 Cells
Shortly after the discovery of Lgr5, several other markers (Bmi-1, Lrig1, Hopx, m-Tert) were reported
to preferentially mark a population of quiescent cells located above the uppermost Paneth cell, the +4
position, which do not contribute substantially to epithelial homeostasis, but can support epithelial
reconstitution following injury [119–122].
The polycomb complex protein Bmi-1, which regulates hematopoietic and neural stem cell
self-renewal, was observed to mark a radio-resistant +4 cell population [120]. In vivo lineage tracing
with Bmi-IRES-CreERT2 mice demonstrate Bmi-1+ cells are multipotent, but do not contribute to
epithelial homeostasis under basal conditions [120,123]. While Bmi-1+ cells do participate in epithelial
regeneration in response to injury (discussed later), the validity of Bmi-1 as a specific marker of +4 cells
was brought into question. Independent analysis show Bmi-1 expression overlaps substantially with
Lgr5+ cells [111,119,122,124] and lineage tracing can initiate anywhere in the crypt, including Lgr5+
cells, and over time, most of these clonal populations are shed from the epithelium demonstrating
they originated in short-lived progenitors/stem cells [111]. However, hierarchical clustering of ISC
populations by bulk and single-cell mRNA-seq show enteroendocrine (EE) gene signature enrichment
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in Bmi-1+ cells, which display clonogenic potential ex vivo, suggesting that stem cell activity resides
in a subset of Bmi-1+ cells [125,126]. In addition, Bmi-1+ cells are not sensitive to Wnt signalling,
as demonstrated by the failure of crypt expansion and atrophy following R-Spo and Dickkopf-1 (Dkk1)
treatment respectively, which indicate a functional distinction between Lgr5+ and Bmi-1+ cells [123].
Increased telomerase expression is a desirable trait for stem cells, which buffers against
replication-induced senescence. Indeed, loss of telomerase induces crypt-villus atrophy, suggesting
a functional role for telomerase maintenance in ISCs [127,128]. Prompted by this hypothesis, Montgomery
et al. report a population of rare quiescent cells located in the lower crypt, around the +4 position, labelled
by mouse-telomerase reverse transcriptase (m-Tert) [122]. m-Tert+ cells are radio-resistant and distinct from
Lgr5+ cells. In vivo lineage tracing demonstrates a small percentage of m-Tert+ cells are actively cycling
stem cells that contribute to intestinal homeostasis [122]. Second-generation Tert knock-in reporter animals
(TertTCE/+) confirm previous reports of label-retaining qualities displayed by Tert+ cells, but also reveal
Tert expression overlaps with ChgA+ cells, which is consistent with multi-capable EE lineages [27,125].
Furthermore, injury-induced activation of Tert+ cells requires Wnt2b signalling, highlighting Wnt as
a critical component of successful epithelial recovery following injury [27]. Collectively, these results
support m-Tert as being a marker of an independent, quiescent damage-inducible population of ISCs [73].
A prominent mitogen that regulates ISCs is Epidermal Growth Factor (EGF) signalling [101].
As such, EGF must be diligently regulated to avoid excessive signalling, which is linked to many
epithelial malignancies [129,130]. The leucine-rich repeats and immunoglobulin-like domain 1
(Lrig1) gene encodes a single-pass transmembrane receptor that functions as an inhibitor of ErbB
signalling in several tissues and marks interfollicular epidermal stem cells [131]. Lineage tracing
with Lrig1-IRES-CreERT2 mice, initiated at +4 position, produce long-lived multipotent clonal units
throughout the small intestine [119]. Indeed, models of intestinal injury mobilise Lrig1+ cells to
proliferate and regenerate the colonic epithelium [119]. Furthermore, comparative expression analysis
of Lrig1+ and Lgr5+ cells reveal different transcriptome profiles, supporting their independence
as makers of intestinal (small & large) stem cells [119]. However, an independent study reports
contrasting data, bringing into question the specificity of Lrig1 as a marker of ISCs [132]. In-situ and
immunohistochemical analyses confirmed the expression of Lrig1 in the crypts, however, transcriptome
analysis reveal an enrichment of Lrig1 expression in Lgr5+ cells [132], which is consistent with
fluorescent in situ hybridisation (FISH) showing Lrig1 expression throughout the intestinal crypt [111].
Together these studies highlight an important role for Lrig1 in regulating ErbB signalling in the
intestinal crypt, however the broad expression of Lrig1 and enrichment in Lgr5+ cells suggest it is not
a specific marker of +4 ISCs.
The Hopx gene codes for an atypical homeobox protein, which is expressed mainly in the +4 cells of
the intestine [121]. Hopx+ cells are quiescent, radio-resistant and can restore the epithelium following
radiation-induced damage. Unlike Bmi-1+ cells, in vivo lineage tracing from Hopx-IRES-CreERT2
mice produce multipotent, long-lived clonal tracings throughout the intestinal epithelium [121].
Furthermore, expression profiling of Hopx+ cells and immediate progeny revealed Hopx-derived cells
express high levels of Lgr5 [121]. Conversely, ex vivo organoid cultures derived from isolated Lgr5+
intestinal stem cells can give rise to Hopx+ cells. Taken together, these observations support a model
in which actively proliferating Lgr5+ cells and quiescent Hopx+ cells occupy separate positions within
the intestinal crypt and can interconvert to maintain epithelial homeostasis and regeneration.
Overall, the discrepancies between Potten’s original observations of +4 cells and more recent
reports highlight differences in radiosensitivity and mitotic activity, which make it difficult to
distinguish whether markers of +4 cells truly represent a distinct class of stem cell or whether they are
simply progeny of Lgr5+ CBCs that inherit and express different molecular features as they migrate
away from the crypt base. However, the gastric epithelium also has distinct populations of stem cells,
with several genes identified as markers of reserve stem cells, suggesting that redundancy in stem cells
could be an evolutionary conserved function in the GI tract to help it cope with the harsh conditions
encountered in this tissue.
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2.6. Intestinal Plasticity
Following the identification of various ISC markers, questions about ISC hierarchy have
been intensely studied. For instance, are ISCs functionally equivalent and are they required
during homeostasis and/or regeneration? Given the remarkable capacity of the intestine to
regenerate [133,134], models of intestinal regeneration have been utilised to tease-apart the functional
requirement of various ISC populations. Calvin Kuo’s group took advantage of differences in
sensitivity to ionising radiation to show Bmi-1+ cells are mobilised through epigenetic remodelling
to restock the depleted Lgr5+ population and restore the epithelium [123,125]. Similarly, Hopx+
cells can restore the intestinal epithelium following damage, supporting the notion of a dedicated
reserve stem cell pool [106]. However, using a diphtheria-toxin (DT) inducible transgenic mouse
(Lgr5-EGFP-DTR) to selectively ablate Lgr5+ cells highlights the requirement of Lgr5+ cells during
intestinal regeneration [135]. Under these conditions (DT + 10γ radiation), the regenerative capability
of the intestinal epithelium is significantly impaired, demonstrating that Bmi-1+ and/or Hopx+ cells
are unable to mediate efficient intestinal regeneration [135]. Of note, Lgr5 expression is detected
in a modest proportion of +4 cells [124], which would also be targeted in experiments using the
Lgr5-EGFP-DTR mouse. Interestingly, using the same mouse model to selectively ablate the Lgr5+
population under basal conditions reveal no gross alterations to epithelial homeostasis, which is
compensated by the activation of Bmi-1+ cells [136]. Importantly, the rapid replacement of Lgr5+
ISCs following ablation has been reconciled by the inherent plasticity of lineage-specific precursor
populations. For instance, label-retaining secretory precursor cells, which express a range of ISC
markers (Lrig1, Bmi-1, Lgr5), under basal conditions give rise to short-lived clones comprised of
cells of the secretory lineage [137,138]. Much like the +4 ‘reserve’ population, following injury,
secretory precursor cells can generate all epithelial lineages, demonstrating they can de-differentiate
into functional multipotent stem cells that subsequently reconstitute the intestinal epithelium [137,138].
Similarly, cells expressing the enterocyte differentiation marker alkaline-phosphatase intestinal (Alpi)
can be induced to de-differentiate and replenish the Lgr5+ ISC pool following injury [139]. Collectively,
these studies suggest a model where actively cycling Lgr5+ CBCs are responsible for the daily turn-over
of the intestinal epithelium, whereas a quiescent subset of CBC progeny can restock the active stem cell
pool and intestinal epithelium following cytotoxic insult [6]. More importantly, these studies highlight
that ISC identity is not an intrinsic quality, but rather defined by a cell’s location within the crypt and
exposure to extrinsic ISC promoting factors, including Wnt signals. This current model reconciles the
once irreconcilable stem cell zone and +4 models.
2.7. Wnt Signalling Is Critical for ISCs
Wnt signalling plays a critical role in the mammalian intestinal epithelium where it regulates
stem cell behaviour, proliferation, cellular differentiation, apoptosis and migration (Table 1). Indeed,
much of our understanding concerning the role of Wnt signalling in homeostasis, stem cell biology
and disease have originated from studies in the intestinal epithelium as it is a highly dynamic and
well characterised system amenable to vast experimentation.
As mentioned earlier, the prominent phenotype observed in Tcf-4 mutant animals highlight
a critical role for Wnt signalling in the intestine. Indeed, Tcf-4 knockdown downregulates key Wnt
target genes involved in proliferation and cell-cycle progression such as Myc, which normally represses
the action of cell-cycle inhibitors such as p21, permitting cell-cycle arrest [92]. Conditional deletion of
Myc from the intestinal epithelium causes reduced biosynthetic activity and crypt atrophy, which is
countered by rapidly clearing Myc-deficient cells from the epithelium, highlighting a critical role for
Wnt signalling in maintaining ISC proliferation [140]. Similarly, over-expression of Dkk1 suppresses
Wnt/β-catenin target gene expression resulting in severe lack of proliferative crypts, reminiscent
of the phenotype observed in Tcf-4 mutant mice [16,89,90]. Conversely, hyperactivation of Wnt
signalling is sufficient to impose a crypt-progenitor phenotype characterised by mis-localisation
of differentiated cell types, impaired differentiation and crypt hyperplasia. Such phenotypes
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are typically achieved by establishing a situation where β-catenin is unable to be regulated by
the destruction complex or by administering the potent Wnt agonist R-Spo [17,141]. However,
the latter context is sufficient to bolster the resilience of ISCs following chemoradiotherapy, thereby
improving recovery while targeting tumour tissue [142]. Furthermore, conditional deletion of CTNNB1
(encodes for β-catenin) from the intestinal epithelium disrupts secretory cell specification and triggers
rapid repopulation of the epithelium with β-catenin-proficient cells [88]. Studies investigating
the mechanisms of how Wnt/β-catenin signalling activates key target genes in the intestine have
identified other components of the Tcf/β-catenin transcription complex that play key roles in intestinal
homeostasis. Both Brahma-related gene-1 (Brg1) and leukaemia-associated Mllt10/Af10-Dot1l are
essential Tcf/β-catenin co-activators required for target gene transcription [143,144]. Targeted deletion
of Brig1 or Mllt10/Af10-Dot1l from ISCs results in rapid epithelial repopulation and proliferative defects
observed in intestinal crypts respectively [143,144].
Competition for niche space is a defining feature in determining ISC identity. Wnt is a central
component of the ISC niche, which is provided by neighbouring Paneth cells [80], yet, ablation of
Paneth cells reveals no obvious changes to ISCs or intestinal homeostasis [145]. This may have
been due to incomplete deletion of all Paneth cells, but nonetheless, conditional deletion of Wnt3,
the Wnt released by Paneth cells that is required for stem cell function [80], or inhibition of Wnt
secretion (conditional deletion of Porcupine or Wntless) from the epithelium also reveal no change to
ISC homeostasis. These data suggest that the surrounding stroma can provide an alternate source of
Wnt ligands, and it was recently demonstrated that Wnt2b is secreted by sub-epithelial mesenchymal
cells to activate ISCs in situations of Paneth cell shortage [15,28,146]. As mentioned, Wnt is paramount
to ISC maintenance, which is reflected by the necessity of Wnt and R-Spo in establishing Lgr5+-derived
organoid cultures [101]. Indeed, mesenchymal cells can rescue Wnt-depleted organoid cultures
through supplying ISCs with critical Wnts and R-Spo ligands [15]. From the perspective of the ISC,
Wnt ligands expressed by Paneth cells (Wnt3a, 6 and 9b) are directly sequestered via binding to
Fzd receptors expressed on the surface of ISCs, rather than via intercellular diffusion [33,80,91,147].
We have shown Fzd7 to be the major Fzd expressed by Lgr5+ ISC and deletion of Fzd7 is sufficient
to induce transient depletion of the ISC pool [14]. In addition to its function as a marker of ISCs,
Lgr5 encodes for a 7-transmembrane protein that participates in the Wnt receptor complex where it
binds R-Spo [148–150] to prohibit the ubiquitylation of Fzd receptors by E3 ligases Znrf3/Rnf43,
thereby stabilising Fzd expression, and thus potentiating Wnt signal strength [151,152]. Hence,
the R-Spo/Lgr5/Znrf3/Rnf43 signalling axis fine-tunes the level of Wnt at the crypt base, ensuring
highest levels are achieved in cells destined for an ISC fate. Indeed, perturbations to any of these Wnt
signal regulators induces dramatic changes to the dynamics of the ISC pool and ultimately intestinal
homeostasis [141,148,151–153]. Recent work has elucidated the roles of Wnt and R-Spo to suggest that
R-Spo ligands adopt the primary instructive role in ISC maintenance and proliferation, whilst Wnt
ligands confer basal proliferative competence to ISCs through maintaining suitable levels of the R-Spo
receptor Lgr5. Thus, in this model, intestinal homeostasis is dictated by the abundance of R-Spo ligand,
with Wnt serving to prime the cells which will respond to this signal by upregulating Lgr5 [154].
2.8. Aberrant Wnt Signalling Triggers Intestinal Tumourigenesis
As mentioned previously, deregulated Wnt signalling is linked to the progression of cancer,
most notably CRC [155] (Table 1). Of the three broad phases that encompass CRC tumour evolution,
the initiating or ‘breakthrough’ phase is often triggered by truncating mutations to APC, providing cells
with a growth advantage that progress to small adenomas in the colon [156]. Subsequent mutation to
key driver-genes (Kras, Smad4, p53) permit cells to invade and grow in otherwise hostile environments,
which over many years progress to adenocarcinoma [157]. Hyperactivated Wnt signalling in CRC
can also arise from mutations to AXIN2 [158] or CTNNB1 (β-catenin) [85], but account for a small
percentage of cases in comparison to APC. While the kinetics by which APC is mutated differs between
FAP and sporadic CRC patients, tumour cells with truncating APC mutations that maintain a ‘just-right’
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level of Wnt signalling are positively selected for optimal tumour growth [159]. Mouse models of both
FAP and sporadic CRC show substantial variation in disease onset and severity based on the nature
of Apc mutation [160,161], which supports the idea of a ‘just-right’ or ‘Goldilocks’ amount of Wnt
signalling as a driver of tumour formation, rather than an “on-off” switch of excessive Wnt activation.
Conditional truncation of Apc in the intestinal epithelium instantly transforms the epithelium, causing
an expansion of ISCs and disruption to epithelial homeostasis [17]. The growth of Apc-mutant cells
requires the Wnt target Myc, which upon co-deletion rescues the intestinal phenotypes induced by
Apc mutation [162]. Furthermore, restoration of wild-type Apc alone is sufficient to block intestinal
tumour growth, despite concurrent mutations in oncogenes Kras, Smad4 and the tumour suppressor
p53, which highlight the clinical importance of controlling Wnt in CRC [163].
Although these early studies provide invaluable insight into the consequences following Apc
mutation in the intestine, cancer genome sequencing has revealed new kinds of CRC mutations that
deregulate Wnt signalling [164,165]. Whole-exome sequencing of patient tumour-matched samples
reveal loss-of-function (LOF) mutations to RNF43, which negatively regulate Fzd receptors, in 18.9% of
CRCs, showing a higher prevalence in microsatellite instable (MSI) tumours [164]. Moreover, RNF43
mutations are mutually exclusive to APC mutations [164]. Conditional deletion of both Znrf3 and Rnf43
from the intestinal epithelium induces rapid expansion of Lgr5+ ISCs and subsequent hyperactivation
of Wnt signalling, quickly leading to adenoma formation [151]. Similarly, recurrent gene fusions
between R-SPO2 and R-SPO3 are observed in 10% of CRCs [165], which like RNF43, are mutually
exclusive to APC mutations, indicating a role for R-SPO in Wnt activation in CRC formation. As such,
human CRC xenografts treated with a R-SPO3 blocking antibody promotes cell differentiation and
decreased Lgr5+ ISC function. Interestingly, a modest reduction in the expression of several Wnt target
genes, AXIN2, MYC and CCND1, is observed following anti-R-SPO3 treatment, suggesting therapies
targeting R-SPO in the intestine will be well tolerated [166].
Considering the remarkable plasticity of the intestine and long-standing cancer-stem-cell (CSC)
theories [7], a question that persists in the field is whether all epithelial cells are equivalent in their
tumour forming capability, or are stem cells the only cell type endowed with the potential to give
rise to a tumour? Support for the latter hypothesis was shown following targeted activation of Wnt
signalling in Lgr5+ or Bmi-1+ ISCs, which lead to rapid adenoma formation [8,120]. In contrast,
activation of Wnt signalling in enterocytes failed to yield established adenomas [8]. More recently,
two independent approaches have shown LGR5+ cell ablation in human and mouse CRC organoid
xenografts is sufficient to induce tumour remission, further supporting a ‘bottom-up’ CSC model for
CRC [167]. However, following the cessation of LGR5+ cell ablation, mobilisation of LGR5- cells quickly
reinstated tumour growth [168,169], which may undermine the clinical translation of CSC-targeted
therapies. Indeed, plasticity within CRC has been previously reported, owing to extrinsic cues from
the tumour microenvironment that induce transformation of differentiated epithelial cells through Wnt
activation [170]. Similarly, terminally differentiated enterocytes or DCLK1+ tuft-cells re-express ISC
markers (Lgr5, Ascl2, Rnf43) and acquire tumour-forming capacity following simultaneous stimulation
of Wnt and inflammation pathways, which support a ‘top-down’ model of CRC initiation [171,172].
Likewise, TGFβ signalling from the stroma limits the capacity of terminally differentiated enterocytes
to de-differentiate following Wnt and MAPK activation, stressing the importance of targeting both
cell intrinsic and extrinsic cues in CRC cells [173]. Moreover, elegant work from Simon Leedham’s
group show genetic disruption of intestinal morphogen gradients via GREM1 overexpression enables
the persistence of Lgr5- cells to form ectopic crypts on the flanks of villi. This demonstrates selective
pressures that disturb homeostatic balance, such as morphogen dysregulation, can cause committed
progenitor cells and even some differentiated cells to regain stem cell properties [174]. Collectively,
these studies depict a challenging obstacle to successfully treat CRC given the plasticity of differentiated
cells to acquire stem cell properties. Thus, it may be an attractive therapeutic approach to target the
CSCs and also the niche that provides these signalling cues, including the Wnt pathway.
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3. Gastric Stem Cells and Wnt Signalling
3.1. Gastric Biology
Due to the dynamic function of the stomach, the gastric epithelium is replenished continually,
fuelled by a small population of resident adult stem cells [175]. Like the intestine, the gastric
epithelium is organized into numerous glandular mucosal invaginations referred to as gastric units,
which house stem cells and various differentiated cells responsible for the regular function of the
stomach. Gastric units comprise of the flask-shaped gland, which can be subdivided into the isthmus,
neck, base and the pit which is continuous with the surface epithelium (Figure 1B). The four terminally
differentiated cell types include parietal cells which secrete hydrochloric acid and a number of other
factors including HB-EGF, TGF-α and Shh [176], chief cells with pepsinogen granules secreting active
pepsin, two types of gastric mucus cells (surface mucous cells and mucous neck cells) secreting
Muc5AC and Trefoil Factor-1 (Tff1) or Muc6 and Tff2 respectively [177] as well as several types
of hormone-secreting enteroendocrine cells [103]. These lineages differentiate from progenitor cell
populations located in the upper neck region of the gastric glands [178].
The glandular stomach is comprised of the proximal corpus and the distal antrum with the precise
cellular composition, architecture and turnover rate varying significantly between the two (Figure 2).
The interface between the corpus and the antrum is not abrupt but marked by transitional mucosae that
shares features of both [179]. The gastric units of the antrum comprise several short glands that feed
into a single extended pit. They have a simple cellular composition characterized by abundant gastric
alkaline mucous-secreting cells, endocrine cells (G-cells), and low numbers of acid-secreting parietal
cells [180,181]. The hydrochloric–secreting parietal cells aide in digestion of food and maintain the
acidic pH of the stomach. Large quantities of mucous produced by the mucous-secreting cells protect
the duodenum from hydrochloric acid following the emptying of the stomach while the G-cells secrete
a variety of hormones that regulate digestion and absorption, such as Ghrelin and Somatostatin [182].
Figure 2. Stem cell populations and signalling gradients of the gastric epithelium. Schematic of the
gastric epithelium depicting the various cell types, stem cell populations and signalling gradients.
The antral (a) and corpal (b) epithelium are shown on the left and right respectively.
In contrast, the corpus gastric units are comprised of several longer tubular glands that feed into
short pits. The corpus epithelium is more heterogeneous than that of the antrum, containing many
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more parietal cells in addition to chief cells, base and neck located mucus cells, and endererndrone
cells [175]. Mucous neck cells function in a secretory fashion as well as an intermediate progenitor
for chief cells. The chief cells work in conjunction with the HCl-secreting parietal cells and release
chymosin and pepsinogen, which is converted to pepsin in acidic conditions thus reflecting its role as
the major digestive unit of the stomach [160].
The mechanisms and factors that regulate the homeostasis of the gastric epithelium have only
been partially characterized. However, aberrations in these mechanisms, most frequently due to
chronic inflammation, can lead to oxyntic atrophy (loss parietal cells) and give rise to Spasmolytic
Polypeptide-expressing Metaplasia (SPEM); an event linked to the initiation of both dysplasia and
neoplasia [183]. SPEM was first studied in models of acute parietal cell loss using compounds (DMP-777
and L635) to induce parietal cell death via targeted inhibition of protoniophores [184], with similar
parietal cell toxicity effects observed following high-dose tamoxifen administration [185]. Although
the current understanding is that gastric metaplasia is triggered by the loss of the parietal cells, it has
been noted that loss of chief cells also occurs during oxyntic atrophy and recent data postulates that
the two processes may be linked. Lineage tracing from chief cells, using the Mist1-CreERT2:LSL-LacZ
mice identified that SPEM lineages were mainly derived from chief cells which undergo zymogen
granule atrophy and changes in gene expression, including upregulation of Tff2 [186]. Thus, SPEM is
a feature that develops in response to gastric mucosal injury, suggesting SPEM aids in regeneration,
and in common to the intestine, this is a process that can be hi-jacked by oncogenes or loss of tumour
suppressors to initiate tumourigenesis, and consequently SPEM is linked with an increased risk of
gastric neoplasia [184,187].
3.2. Gastric Stem Cells
Gastric epithelial cells are exposed to considerable chemical stress, including low pH and
exogenous toxins, and physical stresses from peristaltic contractions of the stomach. To function
in this situation, the epithelium has a rapid turnover of cells fuelled by resident populations of stem
cells. The corpus and antrum gland are functionally and morphologically distinct and therefore have
very different stem cell populations, and turnover rates, with the corpus taking 10–30 days and the
antrum much faster at around 7–10 days [175]. Early studies used radioactive nucleotides to label
differentiated progenitor populations to investigate gastric epithelial proliferation dynamics [188].
However, the subsequent generation of transgenic mice to mark the progeny of specific cell types via
lineage tracing, which is considered the gold-standard to assay stem cell function in vivo, has permitted
the identification of several gastric stem cell markers, which will be the focus of the following sections.
The search for gastric stem cell markers revealed that there were several populations of active
stem cells and reserve stem cells per gland, often with common genes marking populations in both
the antrum and corpus. Homeostasis of the corpal epithelium is maintained by stem cells located
in the highly proliferative isthmus region marked by Mist1, Runx1, Sox2 and Troy, although lineage
tracing has been observed occasionally from Troy+ cells located in the base [32]. However, there is
a population of reserve stem cells located in the base of the corpus gland which can give rise to whole
corpus glands in response to injury which is marked by several genes including Mist1, Lgr5, Runx1,
Sox2 and Troy [189–192]. Four stem cell markers have been identified in the antrum; Lgr5, Sox2, Lrig1
and CCKBR [103,119,189,193], which all contribute to homeostasis of this tissue. Below is a description
of each of the gastric stem cell markers identified to date.
3.3. Lgr5
In 2010 Barker et al identified a small population of rapidly cycling cells that expressed the
Wnt target gene Lgr5 at the base of antral glands [103]. To determine if this population of cells were
stem cells they generated Lgr5-EGFP-IRES-CreERT2/Rosa26lacZ mice and performed lineage tracing
in vivo. Lgr5+ cells were indeed able to give rise to all the differentiated cells of the antral epithelium,
demonstrating they are long-lived multipotent stem cells of the gastric epithelium [88]. Lgr5+ gastric
Genes 2018, 9, 178 14 of 32
stem cells share similar proliferation kinetics with their intestinal counterparts, demonstrating a drift
towards clonality and regular mitotic activity [194]. Isolated Lgr5+ stem cells form long-lived gastric
organoids that closely resembled the antral epithelium, demonstrating this population of cells has
potent stem cell qualities [88]. These gastric organoid cultures require Wnt3a and R-Spo in the culture
medium highlighting that Wnt is needed to maintain the gastric epithelium [103,195].
Similar expression patterns were seen in adult human antrum via in-situ hybridization,
suggesting LGR5 also marks gastric stem cells in humans [103]. However, transgenic silencing of
the Lgr5-EGFP-IRES-CreERT2 locus resulted in variegated expression of this locus and thus limited
the investigation into the full extent of Lgr5 as a stem cell marker. To overcome this, Leushacke et al.
recently developed a non-variegated mouse model, Lgr5-2A-CreERT2, to allow further investigation of
Lgr5. They were now able to detect that Lgr5 was also expressed in a sub-population of chief cells at the
base of corpal glands [191]. Lineage tracing showed that although this population of cells do not give
rise to fully traced glands during homeostasis, they were activated in response to damage, after which
they could give rise to whole corpus glands [191]. This highlights Lgr5-expressing cells as reserve stem
cells in the corpus but as more active stem cells in the antrum where they contribute to daily tissue
homeostasis. Ablation of Lgr5+ cells in the corpus resulted in compromised tissue architecture and
a substantial reduction in the capacity to form corpal stomach organoids [191]. Although these data
indicate the importance of Lgr5 in regulating homeostasis in the corpus they also suggest that reserve
stem cells are functioning to maintain corpus function when Lgr5 is deleted. This is consistent with the
present model of several populations of stem cells co-operating during homeostasis and damage in the
gastric epithelium.
3.4. RunX1
The transcription factor Runx1 is required for the generation of hematopoietic stem cells and
endothelial cells [196], and is expressed in several epithelial tissues including breast [197] and skin [198].
Investigations into the expression of Runx1 in the gastric epithelium via in-situ hybridization (ISH) and
immunofluorescence analyses on tissues from C57BL/6 mice revealed that it marks a population of
highly proliferative cells located in the isthmus [199]. An element of the Runx1 promoter called eR1, was
identified as an enhancer of Runx1 in hematopoietic stem cells [200,201]. Lineage tracing experiments
on the gastric tissue from eR1-CreERT2;Rosa-LSL-tdTomato and eR1-CreERT2;Rosa-LSL-EYFP mice
revealed that eR1 marked a population of stem cells in the isthmus of the corpus and the antrum [185].
These eR1+ stem cells continuously gave rise to differentiated cells to maintain the gastric unit as well
as generated gastric organoid cultures in vitro when co-cultured with Wnt3a, EGF, Noggin and R-Spo.
Rarer Runx1+ chief cells at the base of the corpus can also function as reserve stem cells that function,
along with other populations of gastric stem cells, during repair [185].
3.5. Sox2
The transcription factor Sox2 is expressed in a variety of adult self-renewing epithelia including
oesophageal, lung, intestinal and stomach [189]. Sox2-CreERT2;Rosa26-LSL-EYFP mice identified that
Sox2 is expressed in the corpus and antrum of the gastric epithelium, with some clusters of EYFP
expression demonstrating that some rare Sox2+ cells had expanded over the 4-day pulse period [175].
15–22 months after the treatment fully traced glands in both the corpus and antrum were observed,
suggesting that Sox2+ cells have the ability for self-renewal and can give rise to the mature cell types
of the glandular stomach. The fully traced corpus glands were seen less frequently than the antrum
glands which is consistent with the reported slower turnover rate of corpus cells (3–194 days) compared
with antral cells (1–60 days).
Co-labelling experiments with antibodies that recognized known differentiated cell types of
the stomach showed that Sox2+ cells were negative for all differentiation markers in the antrum
and corpus and therefore are uncommitted stem cells. However, EYFP+ glands originating from
lineage-traced Sox2+ cells 6 months after the treatment showed co-staining of EYFP+ cells with
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markers of enteroendocrine cells, mucus cells, parietal cells and chief cells. It can therefore be concluded
that Sox2+ cells are multipotent stem cells in both the antrum and the corpus and the observation
that labelled glands were still detectable up to 460 days after the treatment highlight Sox2+ cells
self-renewing ability.
Since Barker et al demonstrated that Lgr5 cells are multipotent stem cells in the antrum, it was
important to assess if there was any overlap in the expression patterns of Sox2 and Lgr5. IHC for GFP
and Sox2 on sections of antrum tissue from Lgr5-GFP-IRES-CreERT2 mice showed no overlap in the
expression of Lgr5 and Sox2, suggesting these genes mark district types of stem cells in the antrum.
In the corpus, Troy expression was increased, whilst expression of Sox2 remained unchanged in Lgr5
depleted corpus, suggesting these two populations may contribute to Lgr5-independent renewal [191].
3.6. Lrig1
Leucine-rich repeats and immunoglobulin-like domains 1 (Lrig1), an ErbB negative regulator,
marks a population of multipotent cells in the corpus and antrum. Upon injury, these cells can
proliferate to replace damaged gastric glands. Lineage tracing from Lrig1-CreERT2;R26RLacZ mice
identified that Lrig1 marks a quiescent, long-lived intestinal stem cell population unique from
Lgr5 [119]. Also, Lrig1 marks short- (24 h) and long-term (2 months) cells in the gastric epithelium.
Further studies utilized an Lrig1-CreERT2;R26R-YFP mouse to demonstrate that Lrig1+ cells were
located in the isthmus of the corpus, and towards the bottom, but not the base, of the antrum [202].
Lrig1 is co-expressed with a subset of proliferating cells in both the corpus and the antrum, and a subset
of parietal cells in the corpus [188]. Lrig1+ cells could give rise to long term (1-year post recombination)
gastric lineage epithelial cells in both the corpus and the antrum [188], illustrating it is a marker of
stem cells during homeostasis and injury repair in the gastric epithelium.
Lrig1+ cells can also contribute to the recovery of gastric glands in the corpus after acute oxyntic
injury induced by DMP-777, which is a parietal cell-specific protonophore. DMP-777 treatment of
Lrig1-CreERT2;R26R-YFP mice identified that Lrig1+ cells gave rise to parietal cells (H/K-ATPase),
neck cells (GS-II lectin), proliferating cells, and metaplastic cells (CD44v9) following tissue repair [188].
However, Lrig1 knockout mice treated for three days with DMP-777, were able to recover from acute
gastric mucosal injury, suggesting that Lrig1 protein is not required for regeneration of gastric mucosa
after oxyntic atrophy and lineage differentiation [188].
3.7. Troy
Tumour necrosis factor receptor superfamily, member 19 (TROY), is a member of the TNF-receptor
superfamily. In the stomach, Troy was originally reported to label cells at the base of corpus glands
and pulse labelling from Troy-eGFP-IRES-CreERT2 mice demonstrated that Troy was expressed in
a small population of fully differentiated chief cells [192]. Although Troy+ chief cells do not proliferate,
or if so very rarely, they can form organoids, suggesting they have stem cell properties in specific
situations [178]. Indeed, lineage tracing in Troy-eGFP-IRES-CreERT2 mice showed that fully traced
glands did originate from Troy+ chief cells but at a very slow rate, often taking up to 3 months or
onward after recombination [178]. These data suggest Troy+ chief cells act as reserve stem cells in
the corpus. In support of this, treatment of Troy-eGFP-IRES-CreERT2 mice with 5-fluorouracil (5-FU)
to selectively kill proliferative cells in the isthmus, greatly enhanced the rate and number of lineage
tracing events originating from Troy+ chief cells in the corpus base [178]. Whole-labelled glands have
also been reported to originate from a rare population of Troy+ cells in the isthmus of the corpus [32],
suggesting there are two populations of Troy+ cells in the corpus; one in the isthmus which is able to
lineage trace during normal homeostasis [174], and another in the base of the glands which functions
predominantly as a population of reserve stem cells during healing [203].
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3.8. Mist1
Mist1 is a basic helix-loop-helix transcription factor. Using Mist1-CreERT2-R26-mTmG mice it was
observed that Mist1 is expressed predominantly in chief cells of the lower two thirds of the corpus,
with a rare population also observed in the isthmus [174]. Lineage tracing revealed bi-directional
expansion from a single Mist1+ cells in the isthmus which gave rise to long term, fully traced glands
containing all the differentiated cell types of the corpus [174], illustrating Mist1 marks stem cells
located in the isthmus. Mist1-CreERT2;R26-Confetti mice revealed that Mist1+ isthmus cells gave
rise to blocks of colour expansion, whilst recombination in chief cells did not, thus demonstrating
that Mist1+ cells located in the isthmus are the predominant stem cell in the corpus rather than
chief cells [174]. In support of this, isthmal Mist1+ cells were able to form gastric organoids while
Mist1+ chief cells remained as single cells and did not form organoids. To determine if Mist1+ cells
were giving rise to Lgr5+ cells when cultured for organoid growth, Lgr5 cells were first ablated in
Mist1-CreERT2;Lgr5-DTR;R26-TdTomato mice, however this did not prevent robust organoid culture
from isthmus Mist1+ cells highlighting Mist1+ cells are capable of self-renewal in the absence of
Lgr5+ cells.
3.9. CCK2R
Cholecystokinin B receptor (CCK2R) is the receptor for gastrin and pro-gastrin which are
expressed by G-cells in the antral stomach. CCK2R-CreERT-BAC mice revealed that CCK2R expressing
cells were located at +3 to +7 position above the base of the antral gastric units [193]. Lineage tracing
from CCK2R-CreERT2-BAC;Rosa26TdTomato mice revealed that CCK2R+ cells were able to give rise
to full antral gastric units containing all differentiated cells, and were thus markers of antral stem
cells [179]. In support of this, FACS sorted CCK2R+ cells could grow gastric organoids, whilst CCK2R
negative cells failed to do so. CCK2R+ cells were negative (or very low) for Lgr5 expression, suggesting
they are a distinct population, and are also located slightly above the Lgr5+ population and were
more proliferative [179]. However, treatment of Lgr5neg or low/CCK2R+ gastric cells with progastrin
resulted in rapid interconversion of these cells into Lgr5high cells, thus expanding the pool of active
stem cells in the antrum.
3.10. How Wnt Signalling Regulates Gastric Stem Cells
Wnt signalling is well characterised as a critical signalling pathway regulating homeostasis and
stem cell function in the intestine (Table 1). Among the first reports to demonstrate this were loss of
stem cells and proliferative cells when the Wnt antagonist Dickkopf1 (Dkk1) was overexpressed in the
intestine [89,90], and the failure of crypts to form in Tcf4−/− mice [16]. However, there is growing
evidence that Wnt is also important in the gastric epithelium. Gastric organoid cultures require Wnt3a
and R-Spo in the culture media [103,195] demonstrating that gastric stem cells require Wnt. Indeed,
the first stem cell marker identified in the intestine, Lgr5, is also a marker of gastric stem cells, and has
been identified as a Wnt target gene, and a co-receptor involved in Wnt signalling whereby it promotes
Wnt signalling by associating with R-Spo to titrate RNF43/ZNRF3 and thus reduce the turnover of
Fzd receptors on the cell surface [103,148]. These data highlight that Wnt signalling is active in the
gastric epithelium, with further investigation identifying that Wnt signalling is higher in the antrum
than the corpus [18], although Troy+ cells in the base of the corpus also express Wnt target genes and
stem cell signature genes [192].
There is also evidence of co-operation between Wnt1 and the gastric stem cell marker, and Wnt
target gene CD44. Overexpression of Wnt1 dramatically improves the spheroid formation of gastric
cancer cell lines as well as enriches the side population cells with stem-like properties. Of interest,
CD44 and β-catenin are upregulated in cells overexpressing Wnt1 [204]. Therefore, a subpopulation of
gastric stem cells may be present whereby Wnt1 overexpression increases the relative prevalence of
these cells. CD44 was also upregulated during reprogramming of chief cells, induced by deletion of
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Mist1 as they underwent SPEM, suggesting Wnt may be regulating this process [205]. However, CD44
is also regulated by other pathways in the gastric epithelium, including p-ErK–CD44–pStat3 signalling
that has been demonstrated to regulate SPEM [191].
Detailed analysis of Wnt signalling in the epithelium of the antrum using in situ hybridization
(ISH) showed that several Wnt ligands were expressed (Wnt2b, 3a, 4, 5a, 9a, 9b and 11), and all 10 Fzd
receptors [29]. The expression patterns of some Fzd receptors was focused in specific areas of the
gastric units, for example Fzd10 was expressed predominantly in the pit region, Fzd6 predominantly in
the base, Fzd5 expression was markedly decreased in the gland base, whilst Fzd6 and Fzd7 expression
was mainly confined to the bottom two thirds of the gastric unit [192]. These specific expression
patterns suggest a distinct role for Wnt signalling in each area of the gastric unit, which has yet to be
fully elucidated and will no doubt become clearer in future studies.
Using an Axin2-CreERT2 mouse and ISH, the location of canonical Wnt responsive cells in the
antrum has recently been revealed to be constrained to the gland neck and base [192]. Axin2+ cells
were undifferentiated, and lineage tracing revealed they could give rise to full glands containing
differentiated cells, and thus marked a population of stem cells. Interestingly, only a proportion of
Axin2+ cells co-express Lgr5, and Axin2+ cells were still able to lineage trace in Lgr5DTR mice in
which Lgr5+ cells had been depleted, indicating two distinct populations of Wnt sensitive stem cells
located in the antral gland base [192]. Axin2+/Lgr5− cell activity was regulated by R-Spo3 secreted
by the underlying myofibroblasts in vivo, however, this was not observed for less proliferative Lgr5+
cells that were also insensitive to R-Spo1 or R-Spo3 treatment in vivo [192].
Despite evidence that Wnt signalling is active in the gastric epithelium, it has only recently been
discovered which Fzd receptor transmits these signals. In addition to its expression in the intestinal
epithelium, [14], we have recently shown that Fzd7 is also expressed in the antrum of the gastric
epithelium and deletion of this receptor in vivo is deleterious and triggers rapid repopulation of
the epithelium [18]. This was the first observation that the gastric epithelium has the capacity to
repopulate following genetic insult, in this case deletion of Fzd7, and also the first demonstration that
Wnt signalling is critical in the regulation of the antral epithelium [18]. Fzd7 can transmit signalling
via the canonical and non-canonical pathways. However, in the gastric epithelium Fzd7 is most likely
to be transmitting signals via the canonical pathways since gastric organoid death upon Fzd7 deletion
could be rescued by activating the canonical Wnt pathway at the level of GSK3β [18]. The expression
of several canonical Wnt target genes are reduced following Fzd7 deletion, however, this does not
preclude that non-canonical signalling may still be involved in regulating gastric stem cells, and
homeostasis. Indeed, Wnt5a regulates gastric tumour progression [206], whilst Wnt5a-Ror2 regulates
mesenchymal stem cells to promote the growth of gastric cancer cells [207], suggesting this pathway
may also regulate gastric stem cells. In the intestine, Fzd7 is required for the function of Lgr5+ cells [14].
However, although Fzd7 clearly regulates gastric homeostasis, the exact population of stem cells that
require Fzd7 has yet to be identified.
3.11. The Oncogenic Role of Wnt Signalling in Gastric Cancer
Gastric cancer is a common malignancy with approximately 1,000,000 new cases diagnosed
annually and is the third most common form of cancer-related death world-wide [208]. The largest
proportion of cases are reported from East Asia, South America and Eastern Europe [209].
Gastric cancer is divided histopathologically into two classes: diffuse-type and intestinal-type [210].
However, these broad classifications are dwarfed by the complex pathogenic, environmental and
genomic milieu that ultimately shape the characteristics of any given gastric lesion. In terms of
medical interventions, surgical resection is the first option, but is only effective if gastric tumours are
detected early, which unfortunately is seldom. Encouragingly, various therapies targeting essential
signalling pathways have provided some therapeutic benefit to patients, but are often fraught with
drug-acquired resistance and tumour relapse, highlighting the need to identify other druggable
rate-limiting pathways utilized by gastric cancer cells. Wnt signalling is deregulated in gastric cancer
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at several points along the pathway including the ligand/receptor interface, regulatory proteins and
transcriptional machinery. Moreover, the link between aberrant Wnt signalling and cancer is well
established in many solid tumours including breast, liver and the colon. However, its functional
relevance in gastric cancer is less well characterized. In the following section, we review the extent of
Wnt signal deregulation in the stomach and the cellular and molecular consequences.
Chronic infection with the gram-negative bacteria Helicobacter pylori, which has evolved the
capacity to survive in arguably the most hostile environment of the human body, the stomach, is a major
risk factor for the development of gastric cancer [211]. Following the successful colonization of the
stomach lumen, H. pylori migrates proximally to the stomach epithelium where it delivers bacterial
virulence factors that modulate epithelial biology and inflammatory responses for its own benefit.
Of the virulence factors produced by H. pylori, cytotoxin-associated gene product (CagA) and its
associated type IV secretion system (T4SS) have been shown to activate Wnt signalling and promote
gastric tumourigenesis and progression [211,212]. Thomas Meyer’s group demonstrate that virulent
strains of H. pylori directly inject CagA into gastric epithelial cells, including Lgr5+ gastric stem
cells [213]. Indeed, the number Lgr5+ gastric cells is significantly increased following infection with
H. pylori, which was associated with an increase in Wnt signalling activity and enhanced clonogenic
potential of ex vivo cultures [213]. Further refinement of previous host-pathogen interaction models
reveal a novel population of Wnt responsive Axin2+ gastric stem cells significantly expand following
H. pylori infection, which is associated with an increase in R-Spo3 signalling from subepithelial
myofibroblasts [29]. Indeed, both R-SPO and LGR5 (the receptor for R-SPO) expression are positively
correlated with poor patient survival and outcome [214,215]. Gastric epithelial cells infected with
H. pylori induce the expression and subsequent activation of other Wnt receptor components such
as Fzd [216] and Lrp [217], which propagate Wnt signalling and cell transformation. Collectively,
these data provide a rational therapeutic foundation to target Wnt signalling at the level of the receptor
complex in H. pylori infected gastric cancer cells.
Independent of H. pylori-mediated activation of Wnt signalling, mutation and epigenetic
modification at multiple tiers of the Wnt pathway feature in subsets of gastric cancer patients [218].
For instance, LOF mutations to the E3 ubiquitin-protein ligase RNF43 are reported in 54% and 8% of
MSI and microsattelite stable (MSS) gastric tumours respectively [219]. The functional consequence
of RNF43 mutation allows for FZD receptor stabilization, hyper-sensitivity to available Wnt ligands
and subsequent Wnt activation [151]. Diagnostically, RNF43 mutations occur in early-stage gastric
lesions [220], which could be used to stratify patients who may benefit from compounds that block
the secretion of Wnt ligands, which have substantial efficacy in other ‘Wnt-addicted’ RNF43 mutant
cancers [221,222]. Another common mechanism to de-regulate Wnt signalling is via forced stabilization
of β-catenin, which facilitates robust transcription of Wnt target genes [223], many of which regulate
multiple hallmarks of cancer [224]. Stabilisation and accumulation of β-catenin can occur via truncating
APC [219,225], which is a core component of the β-catenin destruction complex. Of note, allelic
imbalance of APC can be detected in the blood and saliva of patients with gastric adenocarcinoma and
proximal polyposis of the stomach (GAPPS) [226], which place APC as an excellent prognostic marker.
Gastric tumours expressing nuclear β-catenin often harbor gain-of-function mutations in CTNNB1
(encoding β-catenin) [227,228], which permit β-catenin to escape proteosomal degradation and initiate
transcription of target genes involved in cell proliferation and growth [229,230]. As such, targeted
inhibition of β-catenin in gastric cancer cells is sufficient to inhibit Wnt signalling, cell proliferation
and induce apoptosis via suppression of Survivin [231].
Other regulators of the Wnt pathway such as Dickkopf (DKK) and secreted Frizzled-related
protein (sFRP) are epigenetically silenced via promoter hypermethylation in gastric cancer patients,
which permit excessive Wnt activation. Importantly, treatment with de-methylating agents or
exogenous expression of sFRP or Dkk is sufficient to arrest gastric cancer growth in vitro and in
tumour xenografts [232–234]. Interestingly, potent anti-tumour effects of functional Dkk and/or sFRP
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are observed in gastric cancer cells with and without truncating mutations to APC, which provide
compelling evidence that Wnt signalling can be further modulated in APC mutant gastric cancer cells.
Despite the low incidence of genetic lesions to Wnts and Fzd receptors reported in gastric
cancer, aberrant expression of Wnts and Fzd receptors is often observed in gastric tumours [25,218].
The prototypical ‘non-canonical’ Wnt, Wnt5a, which is synonymous with Wnt/β-catenin inhibition
and promotion of cell motility and migration [235], is overexpressed in gastric cancer and correlates
with poor outcome [236]. Hayakawa and colleagues elegantly demonstrate Wnt5a, which is secreted
from a perivascular niche, permit Apc/Kras mutant Mist1+ cells in the corpal stomach to circumvent
anoikis, providing a permissive space for anchorage-independent growth. In support, Wnt5a-deficient
bone marrow chimeras or treatment with polyclonal anti-Wnt5a antibody is sufficient to reduce gastric
tumourigenesis [32,178]. Like its binding counterpart, Fzd receptors show de-regulated expression
in gastric cancer patients [237], which is likely attributed to previously discussed Wnt-activating
mutations. Of the ten mammalian FZDs, FZD7 is overexpressed in gastric cancer at various stages of
disease progression [237–239], which reflects its promiscuous capability to transduce Wnt signalling
via all major signalling arms [14,52]. Together, these data demonstrate gastric cancer cells commonly
display aberrant levels of Wnt signalling, which is rate-limiting for efficient tumour growth and thus,
warrants further investigation into safely targeting Wnt signalling in gastric cancer.
Functional proof that deregulated Wnt signalling can trigger gastric tumourigenesis was first
demonstrated following genetic deletion of Gsk3-β in the mouse gastric epithelium, which developed
intestinal type adenomas [103,240]. The Apc floxed allele has also been used to illustrate that gastric
tumourigenesis can be triggered upon deregulation of Wnt signalling, however, Mist1Cre;Apcfl/fl
mice only develop tumours in the antrum [241], despite robust recombination and deregulation
of Wnt signalling in both the corpus and antrum [32], highlighting that the antrum is more
sensitive to Wnt signalling. Sox2Cre;Apcfl/fl mice develop gastric tumours in the corpus and antrum,
suggesting that each stem cell population in the gastric epithelium has a distinct response to this
level of deregulated Wnt signalling, as gastric tumourigenesis was not observed in the corpus of
Mist1Cre;Apcfl/fl mice [25]. Gastric tumours did develop in the corpus of Mist1Cre;Apcfl/fl;KrasG12D
mice and TroyCre;Apcfl/fl;KrasG12D illustrating a co-operation between Wnt and Kras in gastric
tumourigenesis, and that stem cells are the cell of origin in the gastric epithelium [32]. Indeed,
Lrig1Cre;Apcfl/+ mice also developed gastric tumours in the antrum, as well as the intestine [242].
4. Summary
There is currently a vast body of data highlighting the critical role of Wnt signalling in regulating
many functions of stem cells in the gastric and intestinal epithelium, including survival, proliferation
and clonality. These are also cell functions which are hijacked via aberrant Wnt signalling during
transformation by oncogenes or loss of tumour suppressors, which has also been well documented in
gastric and intestinal cancer, highlighting the importance for strict regulation of the Wnt pathway to
prevent pathologies. It also highlights the great potential to harness these regulatory properties to enable
scientists and clinicians to manipulate cell function to their own specific needs. For example, a transient
increase in proliferation could greatly aid regenerative medicine [243], whilst well defined Wnt activity is
critical for the culture of organoids and tumour organoids from several tissues including the stomach and
intestine [244]. To fully understand how Wnt signalling regulates stem cells, and thus triggers pathologies,
current and future projects are trying to elucidate the complex interactions between the different stem
cell populations and how signalling pathways interact with each other to regulate these functions [245].
A good barometer of the journey left to travel on this research path is the relatively few specific roles that
can be assigned to a single Wnt ligand or receptor which will eventually illuminate the full extent of how
this pathway network regulates this import population of cells.
Acknowledgments: The authors wish to thank Gavan Mitchell for helping generate the figures in this manuscript.
Funding is gratefully acknowledged from the following; National Health and Medical Research Council of
Australia (NHMRC) project grants (566679 and APP1099302 awarded to E.V.); Melbourne Health project grants
Genes 2018, 9, 178 20 of 32
(605030 and PG-002 awarded to E.V./T.J.P.), and an Early Career Researcher grant (GIA-033) awarded to D.J.F.;
Cancer Council of Victoria project grants (CCV, APP1020716) awarded to E.V. and T.J.P., CCV Fellowship awarded
to D.J.F. and Cardiff University Research Fellowship awarded to T.J.P.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Blanpain, C.; Fuchs, E. Stem cell plasticity. Plasticity of epithelial stem cells in tissue regeneration. Science
2014, 344, 1242281. [CrossRef] [PubMed]
2. Weissman, I.L. Stem cells: Units of development, units of regeneration, and units in evolution. Cell 2000, 100,
157–168. [CrossRef]
3. Choumerianou, D.M.; Dimitriou, H.; Kalmanti, M. Stem cells: Promises versus limitations. Tissue Eng.
Part B Rev. 2008, 14, 53–60. [CrossRef] [PubMed]
4. Barker, N.; van Es, J.H.; Kuipers, J.; Kujala, P.; van den Born, M.; Cozijnsen, M.; Haegebarth, A.; Korving, J.;
Begthel, H.; Peters, P.J.; et al. Identification of stem cells in small intestine and colon by marker gene Lgr5.
Nature 2007, 449, 1003–1007. [CrossRef] [PubMed]
5. Li, L.; Clevers, H. Coexistence of quiescent and active adult stem cells in mammals. Science 2010, 327, 542–545.
[CrossRef] [PubMed]
6. Tetteh, P.W.; Farin, H.F.; Clevers, H. Plasticity within stem cell hierarchies in mammalian epithelia.
Trends Cell Biol. 2015, 25, 100–108. [CrossRef] [PubMed]
7. Visvader, J.E. Cells of origin in cancer. Nature 2011, 469, 314–322. [CrossRef] [PubMed]
8. Barker, N.; Ridgway, R.A.; van Es, J.H.; van de Wetering, M.; Begthel, H.; van den Born, M.; Danenberg, E.;
Clarke, A.R.; Sansom, O.J.; Clevers, H. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009,
457, 608–611. [CrossRef] [PubMed]
9. Phesse, T.J.; Buchert, M.; Stuart, E.; Flanagan, D.J.; Faux, M.; Afshar-Sterle, S.; Walker, F.;
Zhang, H.H.; Nowell, C.J.; Jorissen, R.; et al. Partial inhibition of gp130-Jak-Stat3 signaling prevents
Wnt-β-catenin-mediated intestinal tumor growth and regeneration. Sci. Signal. 2014, 7, ra92. [CrossRef]
[PubMed]
10. Fuchs, E.; Tumbar, T.; Guasch, G. Socializing with the neighbors: Stem cells and their niche. Cell 2004, 116,
769–778. [CrossRef]
11. Doupe, D.P.; Alcolea, M.P.; Roshan, A.; Zhang, G.; Klein, A.M.; Simons, B.D.; Jones, P.H. A single progenitor
population switches behavior to maintain and repair esophageal epithelium. Science 2012, 337, 1091–1093.
[CrossRef] [PubMed]
12. Hayakawa, Y.; Sethi, N.; Sepulveda, A.R.; Bass, A.J.; Wang, T.C. Oesophageal adenocarcinoma and gastric
cancer: Should we mind the gap? Nat. Rev. 2016, 16, 305–318. [CrossRef] [PubMed]
13. Nusse, R.; Clevers, H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell 2017,
169, 985–999. [CrossRef] [PubMed]
14. Flanagan, D.J.; Phesse, T.J.; Barker, N.; Schwab, R.H.M.; Amin, N.; Malaterre, J.; Stange, D.E.; Nowell, C.J.;
Currie, S.A.; Saw, J.T.S.; et al. Frizzled7 functions as a Wnt receptor in intestinal epithelial Lgr5(+) stem cells.
Stem Cell Rep. 2015, 4, 759–767. [CrossRef] [PubMed]
15. Kabiri, Z.; Greicius, G.; Madan, B.; Biechele, S.; Zhong, Z.; Zaribafzadeh, H.; Aliyev, J.; Wu, Y.; Bunte, R.;
Rossant, J.; et al. Stroma provides an intestinal stem cell niche in the absence of epithelial Wnts. Development
2014, 141, 2206–2215. [CrossRef] [PubMed]
16. Korinek, V.; Barker, N.; Moerer, P.; van Donselaar, E.; Huls, G.; Peters, P.J.; Clevers, H. Depletion of epithelial
stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat. Genet. 1998, 19, 379–383. [CrossRef]
[PubMed]
17. Sansom, O.J.; Reed, K.R.; Hayes, A.J.; Ireland, H.; Brinkmann, H.; Newton, I.P.; Batlle, E.; Simon-Assmann, P.;
Clevers, H.; Nathke, I.S.; et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation,
and migration. Genes Dev. 2004, 18, 1385–1390. [CrossRef] [PubMed]
18. Flanagan, D.J.; Barker, N.; Nowell, C.; Clevers, H.; Ernst, M.; Phesse, T.J.; Vincan, E. Loss of the Wnt receptor
Frizzled7 in the gastric epithelium is deleterious and triggers rapid repopulation in vivo. Dis. Model. Mech.
2017. [CrossRef] [PubMed]
Genes 2018, 9, 178 21 of 32
19. Van Amerongen, R.; Bowman, A.N.; Nusse, R. Developmental stage and time dictate the fate of
Wnt/β-catenin-responsive stem cells in the mammary gland. Cell Stem Cell 2012, 11, 387–400. [CrossRef]
[PubMed]
20. Burke, Z.D.; Reed, K.R.; Phesse, T.J.; Sansom, O.J.; Clarke, A.R.; Tosh, D. Liver zonation occurs through
a β-catenin-dependent, c-myc-independent mechanism. Gastroenterology 2009, 136, 2316–2324. [CrossRef]
[PubMed]
21. Nusse, R.; Varmus, H.E. Many tumors induced by the mouse mammary tumor virus contain a provirus
integrated in the same region of the host genome. Cell 1982, 31, 99–109. [CrossRef]
22. Nusslein-Volhard, C.; Wieschaus, E. Mutations affecting segment number and polarity in Drosophila. Nature
1980, 287, 795–801. [CrossRef] [PubMed]
23. Clevers, H.; Nusse, R. Wnt/β-catenin signaling and disease. Cell 2012, 149, 1192–1205. [CrossRef] [PubMed]
24. Niehrs, C. The complex world of WNT receptor signalling. Nat. Rev. Mol. Cell Biol. 2012, 13, 767–779.
[CrossRef] [PubMed]
25. Mao, J.; Fan, S.; Ma, W.; Fan, P.; Wang, B.; Zhang, J.; Wang, H.; Tang, B.; Zhang, Q.; Yu, X.; et al. Roles
of Wnt/beta-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment.
Cell Death Dis. 2014, 5, e1039. [CrossRef] [PubMed]
26. Katoh, M. Frequent up-regulation of WNT2 in primary gastric cancer and colorectal cancer. Int. J. Oncol.
2001, 19, 1003–1007. [CrossRef] [PubMed]
27. Suh, H.N.; Kim, M.J.; Jung, Y.S.; Lien, E.M.; Jun, S.; Park, J.I. Quiescence exit of Tert(+) stem cells by
Wnt/β-Catenin is indispensable for intestinal regeneration. Cell Rep. 2017, 21, 2571–2584. [CrossRef]
[PubMed]
28. Farin, H.F.; Van Es, J.H.; Clevers, H. Redundant sources of Wnt regulate intestinal stem cells and promote
formation of Paneth cells. Gastroenterology 2012, 143, 1518–1529. [CrossRef] [PubMed]
29. Sigal, M.; Logan, C.Y.; Kapalczynska, M.; Mollenkopf, H.J.; Berger, H.; Wiedenmann, B.; Nusse, R.;
Amieva, M.R.; Meyer, T.F. Stromal R-spondin orchestrates gastric epithelial stem cells and gland homeostasis.
Nature 2017, 548, 451–455. [CrossRef] [PubMed]
30. Qi, L.; Sun, B.; Liu, Z.; Cheng, R.; Li, Y.; Zhao, X. Wnt3a expression is associated with epithelial-mesenchymal
transition and promotes colon cancer progression. J. Exp. Clin. Cancer Res. 2014, 33, 107. [CrossRef] [PubMed]
31. Miyoshi, H.; Ajima, R.; Luo, C.T.; Yamaguchi, T.P.; Stappenbeck, T.S. Wnt5a potentiates TGF-beta signaling
to promote colonic crypt regeneration after tissue injury. Science 2012, 338, 108–113. [CrossRef] [PubMed]
32. Hayakawa, Y.; Ariyama, H.; Stancikova, J.; Sakitani, K.; Asfaha, S.; Renz, B.W.; Dubeykovskaya, Z.A.;
Shibata, W.; Wang, H.; Westphalen, C.B.; et al. Mist1 expressing gastric stem cells maintain the normal
and neoplastic gastric epithelium and are supported by a perivascular stem cell niche. Cancer Cell 2015, 28,
800–814. [CrossRef] [PubMed]
33. Gregorieff, A.; Pinto, D.; Begthel, H.; Destree, O.; Kielman, M.; Clevers, H. Expression pattern of Wnt
signaling components in the adult intestine. Gastroenterology 2005, 129, 626–638. [CrossRef] [PubMed]
34. Yuan, G.; Regel, I.; Lian, F.; Friedrich, T.; Hitkova, I.; Hofheinz, R.D.; Strobel, P.; Langer, R.; Keller, G.;
Rocken, C.; et al. WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in
human gastric cancer cells. Oncogene 2013, 32, 375–387. [CrossRef] [PubMed]
35. An, C.H.; Kim, S.S.; Kang, M.R.; Kim, Y.R.; Kim, H.S.; Yoo, N.J.; Lee, S.H. Frameshift mutations of ATBF1,
WNT9A, CYLD and PARK2 in gastric and colorectal carcinomas with high microsatellite instability. Pathology
2010, 42, 583–585. [CrossRef] [PubMed]
36. Wu, X.D.; Bie, Q.L.; Zhang, B.; Yan, Z.H.; Han, Z.J. Wnt10B is critical for the progression of gastric cancer.
Oncol. Lett. 2017, 13, 4231–4237. [CrossRef] [PubMed]
37. Nishioka, M.; Ueno, K.; Hazama, S.; Okada, T.; Sakai, K.; Suehiro, Y.; Okayama, N.; Hirata, H.; Oka, M.;
Imai, K.; et al. Possible involvement of Wnt11 in colorectal cancer progression. Mol. Carcinog. 2013, 52,
207–217. [CrossRef] [PubMed]
38. Norollahi, S.E.; Alipour, M.; Rashidy-Pour, A.; Samadani, A.A.; Larijani, L.V. Regulatory Fluctuation of
WNT16 Gene Expression Is Associated with Human Gastric Adenocarcinoma. J. Gastrointest. Cancer 2017.
[CrossRef] [PubMed]
39. Adler, P.N.; Vinson, C.; Park, W.J.; Conover, S.; Klein, L. Molecular structure of frizzled, a Drosophila tissue
polarity gene. Genetics 1990, 126, 401–416. [PubMed]
Genes 2018, 9, 178 22 of 32
40. Vinson, C.R.; Adler, P.N. Directional non-cell autonomy and the transmission of polarity information by the
frizzled gene of Drosophila. Nature 1987, 329, 549–551. [CrossRef] [PubMed]
41. Tamai, K.; Zeng, X.; Liu, C.; Zhang, X.; Harada, Y.; Chang, Z.; He, X. A mechanism for Wnt coreceptor
activation. Mol. Cell 2004, 13, 149–156. [CrossRef]
42. Wehrli, M.; Dougan, S.T.; Caldwell, K.; O’Keefe, L.; Schwartz, S.; Vaizel-Ohayon, D.; Schejter, E.;
Tomlinson, A.; DiNardo, S. arrow encodes an LDL-receptor-related protein essential for Wingless signalling.
Nature 2000, 407, 527–530. [CrossRef] [PubMed]
43. Janda, C.Y.; Waghray, D.; Levin, A.M.; Thomas, C.; Garcia, K.C. Structural basis of Wnt recognition by
Frizzled. Science 2012, 337, 59–64. [CrossRef] [PubMed]
44. Li, V.S.; Ng, S.S.; Boersema, P.J.; Low, T.Y.; Karthaus, W.R.; Gerlach, J.P.; Mohammed, S.; Heck, A.J.;
Maurice, M.M.; Mahmoudi, T.; et al. Wnt signaling through inhibition of beta-catenin degradation in
an intact Axin1 complex. Cell 2012, 149, 1245–1256. [CrossRef] [PubMed]
45. Potten, C.S.; Wilson, J.W.; Booth, C. Regulation and significance of apoptosis in the stem cells of the
gastrointestinal epithelium. Stem Cells 1997, 15, 82–93. [CrossRef] [PubMed]
46. Potten, C.S.; Booth, D.; Haley, J.D. Pretreatment with transforming growth factor beta-3 protects small
intestinal stem cells against radiation damage in vivo. Br. J. Cancer. 1997, 75, 1454–1459. [CrossRef]
[PubMed]
47. Walck-Shannon, E.; Hardin, J. Cell intercalation from top to bottom. Nat. Rev. Mol. Cell Biol. 2014, 15, 34–48.
[CrossRef] [PubMed]
48. Vladar, E.K.; Antic, D.; Axelrod, J.D. Planar cell polarity signaling: The developing cell’s compass. Cold Spring
Harb. Perspect. Biol. 2009, 1, a002964. [CrossRef] [PubMed]
49. Sebbagh, M.; Borg, J.P. Insight into planar cell polarity. Exp. Cell Res. 2014, 328, 284–295. [CrossRef] [PubMed]
50. Anastas, J.N.; Moon, R.T. WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. 2013, 13,
11–26. [CrossRef] [PubMed]
51. Oishi, I.; Suzuki, H.; Onishi, N.; Takada, R.; Kani, S.; Ohkawara, B.; Koshida, I.; Suzuki, K.; Yamada, G.;
Schwabe, G.C.; et al. The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling
pathway. Genes Cells 2003, 8, 645–654. [CrossRef] [PubMed]
52. Phesse, T.; Flanagan, D.; Vincan, E. Frizzled7: A promising Achilles’ heel for targeting the Wnt receptor
complex to treat cancer. Cancers 2016, 8. [CrossRef] [PubMed]
53. Ohkawara, B.; Glinka, A.; Niehrs, C. Rspo3 binds syndecan 4 and induces Wnt/PCP signaling via
clathrin-mediated endocytosis to promote morphogenesis. Dev. Cell 2011, 20, 303–314. [CrossRef] [PubMed]
54. Puvirajesinghe, T.M.; Bertucci, F.; Jain, A.; Scerbo, P.; Belotti, E.; Audebert, S.; Sebbagh, M.; Lopez, M.;
Brech, A.; Finetti, P.; et al. Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK
signalling in breast cancer. Nat. Commun. 2016, 7, 10318. [CrossRef] [PubMed]
55. Yamaguchi, T.; Yanagisawa, K.; Sugiyama, R.; Hosono, Y.; Shimada, Y.; Arima, C.; Kato, S.; Tomida, S.;
Suzuki, M.; Osada, H.; et al. NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival
signaling in lung adenocarcinoma. Cancer Cell 2012, 21, 348–361. [CrossRef] [PubMed]
56. Zhang, S.; Chen, L.; Cui, B.; Chuang, H.Y.; Yu, J.; Wang-Rodriguez, J.; Tang, L.; Chen, G.; Basak, G.W.;
Kipps, T.J. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth.
PLoS ONE 2012, 7, e31127. [CrossRef] [PubMed]
57. Gentile, A.; Lazzari, L.; Benvenuti, S.; Trusolino, L.; Comoglio, P.M. Ror1 is a pseudokinase that is crucial for
Met-driven tumorigenesis. Cancer Res. 2011, 71, 3132–3141. [CrossRef] [PubMed]
58. Rasmussen, N.R.; Debebe, Z.; Wright, T.M.; Brooks, S.A.; Sendor, A.B.; Brannon, A.R.; Hakimi, A.A.;
Hsieh, J.J.; Choueiri, T.K.; Tamboli, P.; et al. Expression of Ror2 mediates invasive phenotypes in renal cell
carcinoma. PLoS ONE 2014, 9, e116101. [CrossRef] [PubMed]
59. Slusarski, D.C.; Yang-Snyder, J.; Busa, W.B.; Moon, R.T. Modulation of embryonic intracellular Ca2+ signaling
by Wnt-5A. Dev. Biol. 1997, 182, 114–120. [CrossRef] [PubMed]
60. Sheldahl, L.C.; Park, M.; Malbon, C.C.; Moon, R.T. Protein kinase C is differentially stimulated by Wnt and
Frizzled homologs in a G-protein-dependent manner. Curr. Biol. 1999, 9, 695–698. [CrossRef]
61. Kreusser, M.M.; Backs, J. Integrated mechanisms of CaMKII-dependent ventricular remodeling.
Front. Pharmacol. 2014, 5, 36. [CrossRef] [PubMed]
62. Acebron, S.P.; Niehrs, C. β-Catenin-independent roles of Wnt/LRP6 signalling. Trends Cell Biol. 2016, 26,
956–967. [CrossRef] [PubMed]
Genes 2018, 9, 178 23 of 32
63. Acebron, S.P.; Karaulanov, E.; Berger, B.S.; Huang, Y.L.; Niehrs, C. Mitotic wnt signaling promotes protein
stabilization and regulates cell size. Mol. Cell 2014, 54, 663–674. [CrossRef] [PubMed]
64. Ishitani, T.; Ninomiya-Tsuji, J.; Nagai, S.; Nishita, M.; Meneghini, M.; Barker, N.; Waterman, M.; Bowerman, B.;
Clevers, H.; Shibuya, H.; et al. The TAK1-NLK-MAPK-related pathway antagonizes signalling between
β-catenin and transcription factor TCF. Nature 1999, 399, 798–802. [CrossRef] [PubMed]
65. Ishitani, T.; Kishida, S.; Hyodo-Miura, J.; Ueno, N.; Yasuda, J.; Waterman, M.; Shibuya, H.; Moon, R.T.;
Ninomiya-Tsuji, J.; Matsumoto, K. The TAK1-NLK mitogen-activated protein kinase cascade functions in
the Wnt-5a/Ca(2+) pathway to antagonize Wnt/β-catenin signaling. Mol. Cell. Biol. 2003, 23, 131–139.
[CrossRef] [PubMed]
66. Mikels, A.J.; Nusse, R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on
receptor context. PLoS Biol. 2006, 4, e115. [CrossRef] [PubMed]
67. Grumolato, L.; Liu, G.; Mong, P.; Mudbhary, R.; Biswas, R.; Arroyave, R.; Vijayakumar, S.; Economides, A.N.;
Aaronson, S.A. Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated
coreceptors. Genes Dev. 2010, 24, 2517–2530. [CrossRef] [PubMed]
68. Topol, L.; Jiang, X.; Choi, H.; Garrett-Beal, L.; Carolan, P.J.; Yang, Y. Wnt-5a inhibits the canonical Wnt
pathway by promoting GSK-3-independent beta-catenin degradation. J. Cell Biol. 2003, 162, 899–908.
[CrossRef] [PubMed]
69. Vincan, E.; Swain, R.K.; Brabletz, T.; Steinbeisser, H. Frizzled7 dictates embryonic morphogenesis:
Implications for colorectal cancer progression. Front. Biosci. J. Virtual Lib. 2007, 12, 4558–4567. [CrossRef]
70. Ueno, K.; Hazama, S.; Mitomori, S.; Nishioka, M.; Suehiro, Y.; Hirata, H.; Oka, M.; Imai, K.; Dahiya, R.;
Hinoda, Y. Down-regulation of Frizzled-7 expression decreases survival, invasion and metastatic capabilities
of colon cancer cells. Br. J. Cancer 2009, 101, 1374–1381. [CrossRef] [PubMed]
71. Holcombe, R.F.; Marsh, J.L.; Waterman, M.L.; Lin, F.; Milovanovic, T.; Truong, T. Expression of Wnt ligands
and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol. Pathol. 2002, 55, 220–226. [CrossRef]
[PubMed]
72. Yan, L.; Du, Q.; Yao, J.; Liu, R. ROR2 inhibits the proliferation of gastric carcinoma cells via activation of
non-canonical Wnt signaling. Exp. Ther. Med. 2016, 12, 4128–4134. [CrossRef] [PubMed]
73. Barker, N. Adult intestinal stem cells: Critical drivers of epithelial homeostasis and regeneration. Nat. Rev.
Mol. Cell Biol. 2014, 15, 19–33. [CrossRef] [PubMed]
74. Clevers, H. The intestinal crypt, a prototype stem cell compartment. Cell 2013, 154, 274–284. [CrossRef]
[PubMed]
75. Pinto, D.; Clevers, H. Wnt control of stem cells and differentiation in the intestinal epithelium. Exp. Cell Res.
2005, 306, 357–363. [CrossRef] [PubMed]
76. Potten, C.S. Extreme sensitivity of some intestinal crypt cells to X and gamma irradiation. Nature 1977, 269,
518–521. [CrossRef] [PubMed]
77. Rothenberg, M.E.; Nusse, Y.; Kalisky, T.; Lee, J.J.; Dalerba, P.; Scheeren, F.; Lobo, N.; Kulkarni, S.; Sim, S.;
Qian, D.; et al. Identification of a cKit(+) colonic crypt base secretory cell that supports Lgr5(+) stem cells in
mice. Gastroenterology 2012, 142, 1195–1205. [CrossRef] [PubMed]
78. Sasaki, N.; Sachs, N.; Wiebrands, K.; Ellenbroek, S.I.; Fumagalli, A.; Lyubimova, A.; Begthel, H.;
van den Born, M.; van Es, J.H.; Karthaus, W.R.; et al. Reg4+ deep crypt secretory cells function as epithelial
niche for Lgr5+ stem cells in colon. Proc. Natl. Acad. Sci. USA 2016, 113, E5399–E5407. [CrossRef] [PubMed]
79. Ireland, H.; Houghton, C.; Howard, L.; Winton, D.J. Cellular inheritance of a Cre-activated reporter gene to
determine Paneth cell longevity in the murine small intestine. Dev. Dyn. 2005, 233, 1332–1336. [CrossRef]
[PubMed]
80. Sato, T.; van Es, J.H.; Snippert, H.J.; Stange, D.E.; Vries, R.G.; van den Born, M.; Barker, N.; Shroyer, N.F.;
van de Wetering, M.; Clevers, H. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts.
Nature 2011, 469, 415–418. [CrossRef] [PubMed]
81. Su, L.K.; Kinzler, K.W.; Vogelstein, B.; Preisinger, A.C.; Moser, A.R.; Luongo, C.; Gould, K.A.; Dove, W.F.
Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992,
256, 668–670. [CrossRef] [PubMed]
82. Kinzler, K.W.; Nilbert, M.C.; Vogelstein, B.; Bryan, T.M.; Levy, D.B.; Smith, K.J.; Preisinger, A.C.;
Hamilton, S.R.; Hedge, P.; Markham, A.; et al. Identification of a gene located at chromosome 5q21 that is
mutated in colorectal cancers. Science 1991, 251, 1366–1370. [CrossRef] [PubMed]
Genes 2018, 9, 178 24 of 32
83. Rubinfeld, B.; Souza, B.; Albert, I.; Muller, O.; Chamberlain, S.H.; Masiarz, F.R.; Munemitsu, S.; Polakis, P.
Association of the APC gene product with beta-catenin. Science 1993, 262, 1731–1734. [CrossRef] [PubMed]
84. Korinek, V.; Barker, N.; Morin, P.J.; van Wichen, D.; de Weger, R.; Kinzler, K.W.; Vogelstein, B.; Clevers, H.
Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC−/− colon carcinoma. Science
1997, 275, 1784–1787. [CrossRef] [PubMed]
85. Morin, P.J.; Sparks, A.B.; Korinek, V.; Barker, N.; Clevers, H.; Vogelstein, B.; Kinzler, K.W. Activation of
β-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275, 1787–1790.
[CrossRef] [PubMed]
86. Sauer, B.; Henderson, N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of
bacteriophage P1. Proc. Natl. Acad. Sci. USA 1988, 85, 5166–5170. [CrossRef] [PubMed]
87. Watanabe, H.; Enjoji, M.; Yao, T.; Ohsato, K. Gastric lesions in familial adenomatosis coli: Their incidence
and histologic analysis. Hum. Pathol. 1978, 9, 269–283. [CrossRef]
88. Ireland, H.; Kemp, R.; Houghton, C.; Howard, L.; Clarke, A.R.; Sansom, O.J.; Winton, D.J. Inducible
Cre-mediated control of gene expression in the murine gastrointestinal tract: Effect of loss of β-catenin.
Gastroenterology 2004, 126, 1236–1246. [CrossRef] [PubMed]
89. Kuhnert, F.; Davis, C.R.; Wang, H.T.; Chu, P.; Lee, M.; Yuan, J.; Nusse, R.; Kuo, C.J. Essential requirement
for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of
Dickkopf-1. Proc. Natl. Acad. Sci. USA 2004, 101, 266–271. [CrossRef] [PubMed]
90. Pinto, D.; Gregorieff, A.; Begthel, H.; Clevers, H. Canonical Wnt signals are essential for homeostasis of the
intestinal epithelium. Genes Dev. 2003, 17, 1709–1713. [CrossRef] [PubMed]
91. van Es, J.H.; Jay, P.; Gregorieff, A.; van Gijn, M.E.; Jonkheer, S.; Hatzis, P.; Thiele, A.; van den Born, M.;
Begthel, H.; Brabletz, T.; et al. Wnt signalling induces maturation of Paneth cells in intestinal crypts.
Nat. Cell Biol. 2005, 7, 381–386. [CrossRef] [PubMed]
92. Van de Wetering, M.; Sancho, E.; Verweij, C.; de Lau, W.; Oving, I.; Hurlstone, A.; van der Horn, K.; Batlle, E.;
Coudreuse, D.; Haramis, A.P.; et al. The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on
colorectal cancer cells. Cell 2002, 111, 241–250. [CrossRef]
93. Cheng, H.; Leblond, C.P. Origin, differentiation and renewal of the four main epithelial cell types in the
mouse small intestine. V. Unitarian Theory of the origin of the four epithelial cell types. Am. J. Anat. 1974,
141, 537–561. [CrossRef] [PubMed]
94. Bjerknes, M.; Cheng, H. Clonal analysis of mouse intestinal epithelial progenitors. Gastroenterology 1999, 116,
7–14. [CrossRef]
95. Potten, C.S. Radiation, the ideal cytotoxic agent for studying the cell biology of tissues such as the small
intestine. Radiat. Res. 2004, 161, 123–136. [CrossRef] [PubMed]
96. Potten, C.S.; Gandara, R.; Mahida, Y.R.; Loeffler, M.; Wright, N.A. The stem cells of small intestinal crypts:
Where are they? Cell Prolif. 2009, 42, 731–750. [CrossRef] [PubMed]
97. Cairns, J. Mutation selection and the natural history of cancer. Nature 1975, 255, 197–200. [CrossRef]
[PubMed]
98. Van der Flier, L.G.; Sabates-Bellver, J.; Oving, I.; Haegebarth, A.; De Palo, M.; Anti, M.; Van Gijn, M.E.;
Suijkerbuijk, S.; Van de Wetering, M.; Marra, G.; et al. The Intestinal Wnt/TCF Signature. Gastroenterology
2007, 132, 628–632. [CrossRef] [PubMed]
99. Snippert, H.J.; van der Flier, L.G.; Sato, T.; van Es, J.H.; van den Born, M.; Kroon-Veenboer, C.; Barker, N.;
Klein, A.M.; van Rheenen, J.; Simons, B.D.; et al. Intestinal crypt homeostasis results from neutral competition
between symmetrically dividing Lgr5 stem cells. Cell 2010, 143, 134–144. [CrossRef] [PubMed]
100. Ritsma, L.; Ellenbroek, S.I.J.; Zomer, A.; Snippert, H.J.; de Sauvage, F.J.; Simons, B.D.; Clevers, H.;
van Rheenen, J. Intestinal crypt homeostasis revealed at single-stem-cell level by in vivo live imaging. Nature
2014, 507, 362–365. [CrossRef] [PubMed]
101. Sato, T.; Vries, R.G.; Snippert, H.J.; van de Wetering, M.; Barker, N.; Stange, D.E.; van Es, J.H.; Abo, A.;
Kujala, P.; Peters, P.J.; et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal
niche. Nature 2009, 459, 262–265. [CrossRef] [PubMed]
102. Jaks, V.; Barker, N.; Kasper, M.; van Es, J.H.; Snippert, H.J.; Clevers, H.; Toftgard, R. Lgr5 marks cycling, yet
long-lived, hair follicle stem cells. Nat. Genet. 2008, 40, 1291–1299. [CrossRef] [PubMed]
Genes 2018, 9, 178 25 of 32
103. Barker, N.; Huch, M.; Kujala, P.; van de Wetering, M.; Snippert, H.J.; van Es, J.H.; Sato, T.; Stange, D.E.;
Begthel, H.; van den Born, M.; et al. Lgr5(+ve) stem cells drive self-renewal in the stomach and build
long-lived gastric units in vitro. Cell Stem Cell 2010, 6, 25–36. [CrossRef] [PubMed]
104. Ng, A.; Tan, S.; Singh, G.; Rizk, P.; Swathi, Y.; Tan, T.Z.; Huang, R.Y.; Leushacke, M.; Barker, N. Lgr5 marks
stem/progenitor cells in ovary and tubal epithelia. Nat. Cell Biol. 2014, 16, 745–757. [CrossRef] [PubMed]
105. Barker, N.; Rookmaaker, M.B.; Kujala, P.; Ng, A.; Leushacke, M.; Snippert, H.; van de Wetering, M.; Tan, S.;
Van Es, J.H.; Huch, M.; et al. Lgr5(+ve) stem/progenitor cells contribute to nephron formation during kidney
development. Cell Rep. 2012, 2, 540–552. [CrossRef] [PubMed]
106. Huch, M.; Dorrell, C.; Boj, S.F.; van Es, J.H.; Li, V.S.; van de Wetering, M.; Sato, T.; Hamer, K.; Sasaki, N.;
Finegold, M.J.; et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration.
Nature 2013, 494, 247–250. [CrossRef] [PubMed]
107. De Visser, K.E.; Ciampricotti, M.; Michalak, E.M.; Tan, D.W.; Speksnijder, E.N.; Hau, C.S.; Clevers, H.;
Barker, N.; Jonkers, J. Developmental stage-specific contribution of LGR5(+) cells to basal and luminal
epithelial lineages in the postnatal mammary gland. J. Pathol. 2012, 228, 300–309. [CrossRef] [PubMed]
108. Huch, M.; Bonfanti, P.; Boj, S.F.; Sato, T.; Loomans, C.J.; van de Wetering, M.; Sojoodi, M.; Li, V.S.; Schuijers, J.;
Gracanin, A.; et al. Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the
Lgr5/R-spondin axis. EMBO J. 2013, 32, 2708–2721. [CrossRef] [PubMed]
109. Chai, R.; Kuo, B.; Wang, T.; Liaw, E.J.; Xia, A.; Jan, T.A.; Liu, Z.; Taketo, M.M.; Oghalai, J.S.; Nusse, R.; et al.
Wnt signaling induces proliferation of sensory precursors in the postnatal mouse cochlea. Proc. Natl. Acad.
Sci. USA 2012, 109, 8167–8172. [CrossRef] [PubMed]
110. Yee, K.K.; Li, Y.; Redding, K.M.; Iwatsuki, K.; Margolskee, R.F.; Jiang, P. Lgr5-EGFP marks taste bud
stem/progenitor cells in posterior tongue. Stem Cells 2013, 31, 992–1000. [CrossRef] [PubMed]
111. Munoz, J.; Stange, D.E.; Schepers, A.G.; van de Wetering, M.; Koo, B.K.; Itzkovitz, S.; Volckmann, R.;
Kung, K.S.; Koster, J.; Radulescu, S.; et al. The Lgr5 intestinal stem cell signature: Robust expression of
proposed quiescent ‘+4’ cell markers. EMBO J. 2012, 31, 3079–3091. [CrossRef] [PubMed]
112. Schuijers, J.; Junker, J.P.; Mokry, M.; Hatzis, P.; Koo, B.K.; Sasselli, V.; van der Flier, L.G.; Cuppen, E.;
van Oudenaarden, A.; Clevers, H. Ascl2 acts as an R-spondin/Wnt-responsive switch to control stemness in
intestinal crypts. Cell Stem Cell 2015, 16, 158–170. [CrossRef] [PubMed]
113. van der Flier, L.G.; van Gijn, M.E.; Hatzis, P.; Kujala, P.; Haegebarth, A.; Stange, D.E.; Begthel, H.;
van den Born, M.; Guryev, V.; Oving, I.; et al. Transcription factor achaete scute-like 2 controls intestinal
stem cell fate. Cell 2009, 136, 903–912. [CrossRef] [PubMed]
114. Jubb, A.M.; Chalasani, S.; Frantz, G.D.; Smits, R.; Grabsch, H.I.; Kavi, V.; Maughan, N.J.; Hillan, K.J.;
Quirke, P.; Koeppen, H. Achaete-scute like 2 (ascl2) is a target of Wnt signalling and is upregulated in
intestinal neoplasia. Oncogene 2006, 25, 3445–3457. [CrossRef] [PubMed]
115. Reed, K.R.; Tunster, S.J.; Young, M.; Carrico, A.; John, R.M.; Clarke, A.R. Entopic overexpression of Ascl2
does not accelerate tumourigenesis in ApcMin mice. Gut 2012, 61, 1435–1438. [CrossRef] [PubMed]
116. Flanagan, J.G.; Vanderhaeghen, P. The ephrins and Eph receptors in neural development. Annu. Rev. Neurosci.
1998, 21, 309–345. [CrossRef] [PubMed]
117. Batlle, E.; Henderson, J.T.; Beghtel, H.; van den Born, M.M.; Sancho, E.; Huls, G.; Meeldijk, J.; Robertson, J.;
van de Wetering, M.; Pawson, T.; et al. Beta-catenin and TCF mediate cell positioning in the intestinal
epithelium by controlling the expression of EphB/ephrinB. Cell 2002, 111, 251–263. [CrossRef]
118. Merlos-Suarez, A.; Barriga, F.M.; Jung, P.; Iglesias, M.; Cespedes, M.V.; Rossell, D.; Sevillano, M.;
Hernando-Momblona, X.; da Silva-Diz, V.; Munoz, P.; et al. The intestinal stem cell signature identifies
colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011, 8, 511–524. [CrossRef] [PubMed]
119. Powell, A.E.; Wang, Y.; Li, Y.; Poulin, E.J.; Means, A.L.; Washington, M.K.; Higginbotham, J.N.; Juchheim, A.;
Prasad, N.; Levy, S.E.; et al. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that
functions as a tumor suppressor. Cell 2012, 149, 146–158. [CrossRef] [PubMed]
120. Sangiorgi, E.; Capecchi, M.R. Bmi1 is expressed in vivo in intestinal stem cells. Nat. Genet. 2008, 40, 915–920.
[CrossRef] [PubMed]
121. Takeda, N.; Jain, R.; LeBoeuf, M.R.; Wang, Q.; Lu, M.M.; Epstein, J.A. Interconversion between intestinal
stem cell populations in distinct niches. Science 2011, 334, 1420–1424. [CrossRef] [PubMed]
Genes 2018, 9, 178 26 of 32
122. Montgomery, R.K.; Carlone, D.L.; Richmond, C.A.; Farilla, L.; Kranendonk, M.E.; Henderson, D.E.;
Baffour-Awuah, N.Y.; Ambruzs, D.M.; Fogli, L.K.; Algra, S.; et al. Mouse telomerase reverse transcriptase
(mTert) expression marks slowly cycling intestinal stem cells. Proc. Natl. Acad. Sci. USA 2011, 108, 179–184.
[CrossRef] [PubMed]
123. Yan, K.S.; Chia, L.A.; Li, X.; Ootani, A.; Su, J.; Lee, J.Y.; Su, N.; Luo, Y.; Heilshorn, S.C.; Amieva, M.R.; et al.
The intestinal stem cell markers Bmi1 and Lgr5 identify two functionally distinct populations. Proc. Natl.
Acad. Sci. USA 2012, 109, 466–471. [CrossRef] [PubMed]
124. Itzkovitz, S.; Lyubimova, A.; Blat, I.C.; Maynard, M.; van Es, J.; Lees, J.; Jacks, T.; Clevers, H.; van Oudenaarden, A.
Single-molecule transcript counting of stem-cell markers in the mouse intestine. Nat. Cell Biol. 2012, 14, 106–114.
[CrossRef] [PubMed]
125. Jadhav, U.; Saxena, M.; O’Neill, N.K.; Saadatpour, A.; Yuan, G.C.; Herbert, Z.; Murata, K.; Shivdasani, R.A.
Dynamic Reorganization of Chromatin Accessibility Signatures during Dedifferentiation of Secretory
Precursors into Lgr5+ Intestinal Stem Cells. Cell Stem Cell 2017, 21, 65–77. [CrossRef] [PubMed]
126. Yan, K.S.; Gevaert, O.; Zheng, G.X.Y.; Anchang, B.; Probert, C.S.; Larkin, K.A.; Davies, P.S.; Cheng, Z.F.;
Kaddis, J.S.; Han, A.; et al. Intestinal enteroendocrine lineage cells possess homeostatic and injury-inducible
stem cell activity. Cell Stem Cell 2017, 21, 78–90. [CrossRef] [PubMed]
127. Breault, D.T.; Min, I.M.; Carlone, D.L.; Farilla, L.G.; Ambruzs, D.M.; Henderson, D.E.; Algra, S.;
Montgomery, R.K.; Wagers, A.J.; Hole, N. Generation of mTert-GFP mice as a model to identify and study
tissue progenitor cells. Proc. Natl. Acad. Sci. USA 2008, 105, 10420–10425. [CrossRef] [PubMed]
128. Rudolph, K.L.; Chang, S.; Lee, H.W.; Blasco, M.; Gottlieb, G.J.; Greider, C.; DePinho, R.A. Longevity, stress
response, and cancer in aging telomerase-deficient mice. Cell 1999, 96, 701–712. [CrossRef]
129. Ljuslinder, I.; Golovleva, I.; Palmqvist, R.; Oberg, A.; Stenling, R.; Jonsson, Y.; Hedman, H.; Henriksson, R.;
Malmer, B. LRIG1 expression in colorectal cancer. Acta Oncol. 2007, 46, 1118–1122. [CrossRef] [PubMed]
130. Miller, J.K.; Shattuck, D.L.; Ingalla, E.Q.; Yen, L.; Borowsky, A.D.; Young, L.J.; Cardiff, R.D.;
Carraway, K.L., 3rd.; Sweeney, C. Suppression of the negative regulator LRIG1 contributes to ErbB2
overexpression in breast cancer. Cancer Res. 2008, 68, 8286–8294. [CrossRef] [PubMed]
131. Jensen, K.B.; Collins, C.A.; Nascimento, E.; Tan, D.W.; Frye, M.; Itami, S.; Watt, F.M. Lrig1 expression
defines a distinct multipotent stem cell population in mammalian epidermis. Cell Stem Cell 2009, 4, 427–439.
[CrossRef] [PubMed]
132. Wong, V.W.; Stange, D.E.; Page, M.E.; Buczacki, S.; Wabik, A.; Itami, S.; van de Wetering, M.; Poulsom, R.;
Wright, N.A.; Trotter, M.W.; et al. Lrig1 controls intestinal stem-cell homeostasis by negative regulation of
ErbB signalling. Nat. Cell Biol. 2012, 14, 401–408. [CrossRef] [PubMed]
133. Bernal, N.P.; Stehr, W.; Zhang, Y.; Profitt, S.; Erwin, C.R.; Warner, B.W. Evidence for active Wnt signaling
during postresection intestinal adaptation. J. Pediatr. Surg. 2005, 40, 1025–1029. [CrossRef] [PubMed]
134. Withers, H.R. Regeneration of intestinal mucosa after irradiation. Cancer 1971, 28, 75–81. [CrossRef]
135. Metcalfe, C.; Kljavin, N.M.; Ybarra, R.; de Sauvage, F.J. Lgr5+ stem cells are indispensable for
radiation-induced intestinal regeneration. Cell Stem Cell 2014, 14, 149–159. [CrossRef] [PubMed]
136. Tian, H.; Biehs, B.; Warming, S.; Leong, K.G.; Rangell, L.; Klein, O.D.; de Sauvage, F.J. A reserve stem cell
population in small intestine renders Lgr5-positive cells dispensable. Nature 2011, 478, 255–259. [CrossRef]
[PubMed]
137. Van Es, J.H.; Sato, T.; van de Wetering, M.; Lyubimova, A.; Nee, A.N.; Gregorieff, A.; Sasaki, N.; Zeinstra, L.;
van den Born, M.; Korving, J.; et al. Dll1+ secretory progenitor cells revert to stem cells upon crypt damage.
Nat. Cell Biol. 2012, 14, 1099–1104. [CrossRef] [PubMed]
138. Buczacki, S.J.; Zecchini, H.I.; Nicholson, A.M.; Russell, R.; Vermeulen, L.; Kemp, R.; Winton, D.J. Intestinal
label-retaining cells are secretory precursors expressing Lgr5. Nature 2013, 495, 65–69. [CrossRef] [PubMed]
139. Tetteh, P.W.; Basak, O.; Farin, H.F.; Wiebrands, K.; Kretzschmar, K.; Begthel, H.; van den Born, M.; Korving, J.;
de Sauvage, F.; van Es, J.H.; et al. Replacement of lost Lgr5-positive stem cells through plasticity of their
enterocyte-lineage daughters. Cell Stem Cell 2016, 18, 203–213. [CrossRef] [PubMed]
140. Muncan, V.; Sansom, O.J.; Tertoolen, L.; Phesse, T.J.; Begthel, H.; Sancho, E.; Cole, A.M.; Gregorieff, A.;
de Alboran, I.M.; Clevers, H.; et al. Rapid loss of intestinal crypts upon conditional deletion of the Wnt/Tcf-4
target gene c-Myc. Mol. Cell. Biol. 2006, 26, 8418–8426. [CrossRef] [PubMed]
Genes 2018, 9, 178 27 of 32
141. Kim, K.A.; Kakitani, M.; Zhao, J.; Oshima, T.; Tang, T.; Binnerts, M.; Liu, Y.; Boyle, B.; Park, E.; Emtage, P.;
et al. Mitogenic influence of human R-spondin1 on the intestinal epithelium. Science 2005, 309, 1256–1259.
[CrossRef] [PubMed]
142. Zhou, W.J.; Geng, Z.H.; Spence, J.R.; Geng, J.G. Induction of intestinal stem cells by R-spondin 1 and Slit2
augments chemoradioprotection. Nature 2013, 501, 107–111. [CrossRef] [PubMed]
143. Holik, A.Z.; Krzystyniak, J.; Young, M.; Richardson, K.; Jarde, T.; Chambon, P.; Shorning, B.Y.; Clarke, A.R.
Brg1 is required for stem cell maintenance in the murine intestinal epithelium in a tissue-specific manner.
Stem Cells 2013, 31, 2457–2466. [CrossRef] [PubMed]
144. Mahmoudi, T.; Li, V.S.; Ng, S.S.; Taouatas, N.; Vries, R.G.; Mohammed, S.; Heck, A.J.; Clevers, H. The kinase
TNIK is an essential activator of Wnt target genes. EMBO J. 2009, 28, 3329–3340. [CrossRef] [PubMed]
145. Durand, A.; Donahue, B.; Peignon, G.; Letourneur, F.; Cagnard, N.; Slomianny, C.; Perret, C.; Shroyer, N.F.;
Romagnolo, B. Functional intestinal stem cells after Paneth cell ablation induced by the loss of transcription
factor Math1 (Atoh1). Proc. Natl. Acad. Sci. USA 2012, 109, 8965–8970. [CrossRef] [PubMed]
146. Valenta, T.; Degirmenci, B.; Moor, A.E.; Herr, P.; Zimmerli, D.; Moor, M.B.; Hausmann, G.; Cantu, C.;
Aguet, M.; Basler, K. Wnt ligands secreted by subepithelial mesenchymal cells are essential for the survival
of intestinal stem cells and gut homeostasis. Cell Rep. 2016, 15, 911–918. [CrossRef] [PubMed]
147. Farin, H.F.; Jordens, I.; Mosa, M.H.; Basak, O.; Korving, J.; Tauriello, D.V.; de Punder, K.; Angers, S.; Peters, P.J.;
Maurice, M.M.; et al. Visualization of a short-range Wnt gradient in the intestinal stem-cell niche. Nature
2016, 530, 340–343. [CrossRef] [PubMed]
148. De Lau, W.; Barker, N.; Low, T.Y.; Koo, B.K.; Li, V.S.; Teunissen, H.; Kujala, P.; Haegebarth, A.; Peters, P.J.;
van de Wetering, M.; et al. Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling.
Nature 2011, 476, 293–297. [CrossRef] [PubMed]
149. Carmon, K.S.; Gong, X.; Lin, Q.; Thomas, A.; Liu, Q. R-spondins function as ligands of the orphan receptors
LGR4 and LGR5 to regulate Wnt/beta-catenin signaling. Proc. Natl. Acad. Sci. USA 2011, 108, 11452–11457.
[CrossRef] [PubMed]
150. Glinka, A.; Dolde, C.; Kirsch, N.; Huang, Y.L.; Kazanskaya, O.; Ingelfinger, D.; Boutros, M.; Cruciat, C.M.;
Niehrs, C. LGR4 and LGR5 are R-spondin receptors mediating Wnt/beta-catenin and Wnt/PCP signalling.
EMBO Rep. 2011, 12, 1055–1061. [CrossRef] [PubMed]
151. Koo, B.K.; Spit, M.; Jordens, I.; Low, T.Y.; Stange, D.E.; van de Wetering, M.; van Es, J.H.; Mohammed, S.;
Heck, A.J.; Maurice, M.M.; et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis
of Wnt receptors. Nature 2012, 488, 665–669. [CrossRef] [PubMed]
152. Hao, H.X.; Xie, Y.; Zhang, Y.; Charlat, O.; Oster, E.; Avello, M.; Lei, H.; Mickanin, C.; Liu, D.; Ruffner, H.;
et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature 2012, 485, 195–200.
[CrossRef] [PubMed]
153. Barry, E.R.; Morikawa, T.; Butler, B.L.; Shrestha, K.; de la Rosa, R.; Yan, K.S.; Fuchs, C.S.; Magness, S.T.;
Smits, R.; Ogino, S.; et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP.
Nature 2013, 493, 106–110. [CrossRef] [PubMed]
154. Yan, K.S.; Janda, C.Y.; Chang, J.; Zheng, G.X.Y.; Larkin, K.A.; Luca, V.C.; Chia, L.A.; Mah, A.T.; Han, A.;
Terry, J.M.; et al. Non-equivalence of Wnt and R-spondin ligands during Lgr5(+) intestinal stem-cell
self-renewal. Nature 2017, 545, 238–242. [CrossRef] [PubMed]
155. Polakis, P. Wnt signaling in cancer. Cold Spring Harb. Perspect. Biol. 2012, 4. [CrossRef] [PubMed]
156. Vogelstein, B.; Kinzler, K.W. The path to cancer—Three strikes and you’re out. N. Engl. J. Med. 2015, 373,
1895–1898. [CrossRef] [PubMed]
157. Kinzler, K.W.; Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 1996, 87, 159–170. [CrossRef]
158. Liu, W.; Dong, X.; Mai, M.; Seelan, R.S.; Taniguchi, K.; Krishnadath, K.K.; Halling, K.C.; Cunningham, J.M.;
Boardman, L.A.; Qian, C.; et al. Mutations in AXIN2 cause colorectal cancer with defective mismatch repair
by activating beta-catenin/TCF signalling. Nat. Genet. 2000, 26, 146–147. [CrossRef] [PubMed]
159. Albuquerque, C.; Breukel, C.; van der Luijt, R.; Fidalgo, P.; Lage, P.; Slors, F.J.; Leitao, C.N.; Fodde, R.;
Smits, R. The ‘just-right’ signaling model: APC somatic mutations are selected based on a specific level of
activation of the beta-catenin signaling cascade. Hum. Mol. Genet. 2002, 11, 1549–1560. [CrossRef] [PubMed]
160. Leedham, S.J.; Rodenas-Cuadrado, P.; Howarth, K.; Lewis, A.; Mallappa, S.; Segditsas, S.; Davis, H.; Jeffery, R.;
Rodriguez-Justo, M.; Keshav, S.; et al. A basal gradient of Wnt and stem-cell number influences regional
tumour distribution in human and mouse intestinal tracts. Gut 2013, 62, 83–93. [CrossRef] [PubMed]
Genes 2018, 9, 178 28 of 32
161. Lewis, A.; Segditsas, S.; Deheragoda, M.; Pollard, P.; Jeffery, R.; Nye, E.; Lockstone, H.; Davis, H.; Clark, S.;
Stamp, G.; et al. Severe polyposis in Apc(1322T) mice is associated with submaximal Wnt signalling and
increased expression of the stem cell marker Lgr5. Gut 2010, 59, 1680–1686. [CrossRef] [PubMed]
162. Sansom, O.J.; Meniel, V.S.; Muncan, V.; Phesse, T.J.; Wilkins, J.A.; Reed, K.R.; Vass, J.K.; Athineos, D.;
Clevers, H.; Clarke, A.R. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007, 446,
676–679. [CrossRef] [PubMed]
163. Dow, L.E.; O’Rourke, K.P.; Simon, J.; Tschaharganeh, D.F.; van Es, J.H.; Clevers, H.; Lowe, S.W. Apc restoration
promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer. Cell 2015, 161,
1539–1552. [CrossRef] [PubMed]
164. Giannakis, M.; Hodis, E.; Jasmine Mu, X.; Yamauchi, M.; Rosenbluh, J.; Cibulskis, K.; Saksena, G.;
Lawrence, M.S.; Qian, Z.R.; Nishihara, R.; et al. RNF43 is frequently mutated in colorectal and endometrial
cancers. Nat. Genet. 2014, 46, 1264–1266. [CrossRef] [PubMed]
165. Seshagiri, S.; Stawiski, E.W.; Durinck, S.; Modrusan, Z.; Storm, E.E.; Conboy, C.B.; Chaudhuri, S.; Guan, Y.;
Janakiraman, V.; Jaiswal, B.S.; et al. Recurrent R-spondin fusions in colon cancer. Nature 2012, 488, 660–664.
[CrossRef] [PubMed]
166. Storm, E.E.; Durinck, S.; de Sousa e Melo, F.; Tremayne, J.; Kljavin, N.; Tan, C.; Ye, X.; Chiu, C.; Pham, T.;
Hongo, J.A.; et al. Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell
function. Nature 2016, 529, 97–100. [CrossRef] [PubMed]
167. Preston, S.L.; Wong, W.M.; Chan, A.O.; Poulsom, R.; Jeffery, R.; Goodlad, R.A.; Mandir, N.; Elia, G.;
Novelli, M.; Bodmer, W.F.; et al. Bottom-up histogenesis of colorectal adenomas: Origin in the monocryptal
adenoma and initial expansion by crypt fission. Cancer Res. 2003, 63, 3819–3825. [PubMed]
168. de Sousa e Melo, F.; Kurtova, A.V.; Harnoss, J.M.; Kljavin, N.; Hoeck, J.D.; Hung, J.; Anderson, J.E.; Storm, E.E.;
Modrusan, Z.; Koeppen, H.; et al. A distinct role for Lgr5(+) stem cells in primary and metastatic colon
cancer. Nature 2017, 543, 676–680. [CrossRef] [PubMed]
169. Shimokawa, M.; Ohta, Y.; Nishikori, S.; Matano, M.; Takano, A.; Fujii, M.; Date, S.; Sugimoto, S.; Kanai, T.;
Sato, T. Visualization and targeting of LGR5(+) human colon cancer stem cells. Nature 2017, 545, 187–192.
[CrossRef] [PubMed]
170. Vermeulen, L.; De Sousa, E.M.F.; van der Heijden, M.; Cameron, K.; de Jong, J.H.; Borovski, T.; Tuynman, J.B.;
Todaro, M.; Merz, C.; Rodermond, H.; et al. Wnt activity defines colon cancer stem cells and is regulated by
the microenvironment. Nat. Cell Biol. 2010, 12, 468–476. [CrossRef] [PubMed]
171. Schwitalla, S.; Fingerle, A.A.; Cammareri, P.; Nebelsiek, T.; Goktuna, S.I.; Ziegler, P.K.; Canli, O.; Heijmans, J.;
Huels, D.J.; Moreaux, G.; et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of
stem-cell-like properties. Cell 2013, 152, 25–38. [CrossRef] [PubMed]
172. Westphalen, C.B.; Asfaha, S.; Hayakawa, Y.; Takemoto, Y.; Lukin, D.J.; Nuber, A.H.; Brandtner, A.; Setlik, W.;
Remotti, H.; Muley, A.; et al. Long-lived intestinal tuft cells serve as colon cancer-initiating cells. J. Clin. Investig.
2014, 124, 1283–1295. [CrossRef] [PubMed]
173. Cammareri, P.; Vincent, D.F.; Hodder, M.C.; Ridgway, R.A.; Murgia, C.; Nobis, M.; Campbell, A.D.; Varga, J.;
Huels, D.J.; Subramani, C.; et al. TGFβ pathway limits dedifferentiation following WNT and MAPK pathway
activation to suppress intestinal tumourigenesis. Cell Death Differ. 2017, 24, 1681–1693. [CrossRef] [PubMed]
174. Biswas, S.; Davis, H.; Irshad, S.; Sandberg, T.; Worthley, D.; Leedham, S. Microenvironmental control of stem
cell fate in intestinal homeostasis and disease. J. Pathol. 2015, 237, 135–145. [CrossRef] [PubMed]
175. Kim, T.H.; Shivdasani, R.A. Stomach development, stem cells and disease. Development 2016, 143, 554–565.
[CrossRef] [PubMed]
176. Beauchamp, R.D.; Barnard, J.A.; McCutchen, C.M.; Cherner, J.A.; Coffey, R.J., Jr. Localization of transforming
growth factor alpha and its receptor in gastric mucosal cells. Implications for a regulatory role in acid
secretion and mucosal renewal. J. Clin. Investig. 1989, 84, 1017–1023. [CrossRef] [PubMed]
177. Ramsey, V.G.; Doherty, J.M.; Chen, C.C.; Stappenbeck, T.S.; Konieczny, S.F.; Mills, J.C. The maturation of
mucus-secreting gastric epithelial progenitors into digestive-enzyme secreting zymogenic cells requires
Mist1. Development 2007, 134, 211–222. [CrossRef] [PubMed]
178. Hanaki, H.; Yamamoto, H.; Sakane, H.; Matsumoto, S.; Ohdan, H.; Sato, A.; Kikuchi, A. An anti-Wnt5a
antibody suppresses metastasis of gastric cancer cells in vivo by inhibiting receptor-mediated endocytosis.
Mol. Cancer Ther. 2012, 11, 298–307. [CrossRef] [PubMed]
Genes 2018, 9, 178 29 of 32
179. Karam, S.M. Cell lineage relationship in the stomach of normal and genetically manipulated mice. Braz. J.
Med. Biol. Res. 1998, 31, 271–279. [CrossRef] [PubMed]
180. Lee, E.R. Dynamic histology of the antral epithelium in the mouse stomach: I. Architecture of antral units.
Am. J. Anat. 1985, 172, 187–204. [CrossRef] [PubMed]
181. Lee, E.R.; Leblond, C.P. Dynamic histology of the antral epithelium in the mouse stomach: IV. Ultrastructure
and renewal of gland cells. Am. J. Anat. 1985, 172, 241–259. [CrossRef] [PubMed]
182. Mills, J.C.; Shivdasani, R.A. Gastric epithelial stem cells. Gastroenterology 2011, 140, 412–424. [CrossRef]
[PubMed]
183. Goldenring, J.R.; Nomura, S. Differentiation of the gastric mucosa III. Animal models of oxyntic atrophy and
metaplasia. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291, G999–G1004. [CrossRef] [PubMed]
184. Nam, K.T.; Lee, H.J.; Sousa, J.F.; Weis, V.G.; O’Neal, R.L.; Finke, P.E.; Romero-Gallo, J.; Shi, G.; Mills, J.C.;
Peek, R.M., Jr.; et al. Mature chief cells are cryptic progenitors for metaplasia in the stomach. Gastroenterology
2010, 139, 2028–2037. [CrossRef] [PubMed]
185. Huh, W.J.; Khurana, S.S.; Geahlen, J.H.; Kohli, K.; Waller, R.A.; Mills, J.C. Tamoxifen induces rapid, reversible
atrophy, and metaplasia in mouse stomach. Gastroenterology 2012, 142, 21–24. [CrossRef] [PubMed]
186. Mills, J.C.; Goldenring, J.R. Metaplasia in the Stomach Arises from Gastric Chief Cells. Cell. Mol. Gastroenterol.
Hepatol. 2017, 4, 85–88. [CrossRef] [PubMed]
187. Lennerz, J.K.; Kim, S.H.; Oates, E.L.; Huh, W.J.; Doherty, J.M.; Tian, X.; Bredemeyer, A.J.; Goldenring, J.R.;
Lauwers, G.Y.; Shin, Y.K.; et al. The transcription factor MIST1 is a novel human gastric chief cell marker
whose expression is lost in metaplasia, dysplasia, and carcinoma. Am. J. Pathol. 2010, 177, 1514–1533.
[CrossRef] [PubMed]
188. Karam, S.M.; Leblond, C.P. Identifying and counting epithelial cell types in the "corpus" of the mouse
stomach. Anat. Rec. 1992, 232, 231–246. [CrossRef] [PubMed]
189. Arnold, K.; Sarkar, A.; Yram, M.A.; Polo, J.M.; Bronson, R.; Sengupta, S.; Seandel, M.; Geijsen, N.;
Hochedlinger, K. Sox2(+) adult stem and progenitor cells are important for tissue regeneration and survival
of mice. Cell Stem Cell 2011, 9, 317–329. [CrossRef] [PubMed]
190. Laoukili, J.; Kooistra, M.R.; Bras, A.; Kauw, J.; Kerkhoven, R.M.; Morrison, A.; Clevers, H.; Medema, R.H.
FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat. Cell Biol. 2005, 7,
126–136. [CrossRef] [PubMed]
191. Leushacke, M.; Tan, S.H.; Wong, A.; Swathi, Y.; Hajamohideen, A.; Tan, L.T.; Barker, N. Lgr5-expressing chief
cells drive epithelial regeneration and cancer in the oxyntic stomach. Nat. Cell Biol. 2017, 19, 774. [CrossRef]
[PubMed]
192. Stange, D.E.; Koo, B.K.; Huch, M.; Sibbel, G.; Basak, O.; Lyubimova, A.; Kujala, P.; Bartfeld, S.; Koster, J.;
Geahlen, J.H.; et al. Differentiated Troy+ chief cells act as reserve stem cells to generate all lineages of the
stomach epithelium. Cell 2013, 155, 357–368. [CrossRef] [PubMed]
193. Hayakawa, Y.; Jin, G.; Wang, H.; Chen, X.; Westphalen, C.B.; Asfaha, S.; Renz, B.W.; Ariyama, H.;
Dubeykovskaya, Z.A.; Takemoto, Y.; et al. CCK2R identifies and regulates gastric antral stem cell states and
carcinogenesis. Gut 2015, 64, 544–553. [CrossRef] [PubMed]
194. Leushacke, M.; Ng, A.; Galle, J.; Loeffler, M.; Barker, N. Lgr5(+) gastric stem cells divide symmetrically to
effect epithelial homeostasis in the pylorus. Cell Rep. 2013, 5, 349–356. [CrossRef] [PubMed]
195. Flanagan, D.J.; Schwab, R.H.; Tran, B.M.; Phesse, T.J.; Vincan, E. Isolation and Culture of Adult Intestinal,
Gastric, and Liver Organoids for Cre-recombinase-Mediated Gene Deletion. Methods Mol. Biol. 2016.
[CrossRef]
196. Chen, M.J.; Yokomizo, T.; Zeigler, B.M.; Dzierzak, E.; Speck, N.A. Runx1 is required for the endothelial to
haematopoietic cell transition but not thereafter. Nature 2009, 457, 887–891. [CrossRef] [PubMed]
197. Banerji, S.; Cibulskis, K.; Rangel-Escareno, C.; Brown, K.K.; Carter, S.L.; Frederick, A.M.; Lawrence, M.S.;
Sivachenko, A.Y.; Sougnez, C.; Zou, L.; et al. Sequence analysis of mutations and translocations across breast
cancer subtypes. Nature 2012, 486, 405–409. [CrossRef] [PubMed]
198. Osorio, K.M.; Lilja, K.C.; Tumbar, T. Runx1 modulates adult hair follicle stem cell emergence and maintenance
from distinct embryonic skin compartments. J. Cell Biol. 2011, 193, 235–250. [CrossRef] [PubMed]
199. Matsuo, J.; Kimura, S.; Yamamura, A.; Koh, C.P.; Hossain, M.Z.; Heng, D.L.; Kohu, K.; Voon, D.C.; Hiai, H.;
Unno, M.; et al. Identification of stem cells in the epithelium of the stomach corpus and antrum of mice.
Gastroenterology 2017, 152, 218–231. [CrossRef] [PubMed]
Genes 2018, 9, 178 30 of 32
200. Ng, C.E.; Yokomizo, T.; Yamashita, N.; Cirovic, B.; Jin, H.; Wen, Z.; Ito, Y.; Osato, M. A Runx1 intronic
enhancer marks hemogenic endothelial cells and hematopoietic stem cells. Stem Cells 2010, 28, 1869–1881.
[CrossRef] [PubMed]
201. Nottingham, W.T.; Jarratt, A.; Burgess, M.; Speck, C.L.; Cheng, J.F.; Prabhakar, S.; Rubin, E.M.; Li, P.S.;
Sloane-Stanley, J.; Kong, A.S.J.; et al. Runx1-mediated hematopoietic stem-cell emergence is controlled by
a Gata/Ets/SCL-regulated enhancer. Blood 2007, 110, 4188–4197. [CrossRef] [PubMed]
202. Choi, E.; Lantz, T.L.; Vlacich, G.; Keeley, T.M.; Samuelson, L.C.; Coffey, R.J.; Goldenring, J.R.; Powell, A.E.
Lrig1+ gastric isthmal progenitor cells restore normal gastric lineage cells during damage recovery in adult
mouse stomach. Gut 2017. [CrossRef] [PubMed]
203. Phesse, T.J.; Sansom, O.J. Lgr5 joins the club of gastric stem cell markers in the corpus. Nat. Cell Biol. 2017,
19, 752–754. [CrossRef] [PubMed]
204. Mao, J.; Fan, S.; Ma, W.; Fan, P.; Wang, B.; Zhang, J.; Wang, H.; Tang, B.; Wang, H.; Zhang, Q.; et al. Roles of
Wnt/β-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment. Cell Death Dis.
2015, 5, e1039. [CrossRef] [PubMed]
205. Khurana, S.S.; Riehl, T.E.; Moore, B.D.; Fassan, M.; Rugge, M.; Romero-Gallo, J.; Noto, J.; Peek, R.M., Jr.;
Stenson, W.F.; Mills, J.C. The hyaluronic acid receptor CD44 coordinates normal and metaplastic gastric
epithelial progenitor cell proliferation. J. Biol. Chem. 2013, 288, 16085–16097. [CrossRef] [PubMed]
206. Yamamoto, H.; Kitadai, Y.; Yamamoto, H.; Oue, N.; Ohdan, H.; Yasui, W.; Kikuchi, A. Laminin γ2 Mediates
Wnt5a-Induced Invasion of Gastric Cancer Cells. Gastroenterology 2009, 137, 242–252. [CrossRef] [PubMed]
207. Takiguchi, G.; Nishita, M.; Kurita, K.; Kakeji, Y.; Minami, Y. Wnt5a-Ror2 signaling in mesenchymal stem
cells promotes proliferation of gastric cancer cells by activating CXCL16-CXCR6 axis. Cancer Sci. 2016, 107,
290–297. [CrossRef] [PubMed]
208. Guggenheim, D.E.; Shah, M.A. Gastric cancer epidemiology and risk factors. J. Surg. Oncol. 2013, 107,
230–236. [CrossRef] [PubMed]
209. Rahman, R.; Asombang, A.W.; Ibdah, J.A. Characteristics of gastric cancer in Asia. World J. Gastroenterol.
2014, 20, 4483–4490. [CrossRef] [PubMed]
210. Lauren, P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type
Carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol. Microbiol. Scand 1965, 64, 31–49.
[CrossRef] [PubMed]
211. Amieva, M.; Peek, R.M., Jr. Pathobiology of Helicobacter pylori-Induced Gastric Cancer. Gastroenterology 2016,
150, 64–78. [CrossRef] [PubMed]
212. Franco, A.T.; Israel, D.A.; Washington, M.K.; Krishna, U.; Fox, J.G.; Rogers, A.B.; Neish, A.S.;
Collier-Hyams, L.; Perez-Perez, G.I.; Hatakeyama, M.; et al. Activation of beta-catenin by carcinogenic
Helicobacter pylori. Proc. Natl. Acad. Sci. USA 2005, 102, 10646–10651. [CrossRef] [PubMed]
213. Sigal, M.; Rothenberg, M.E.; Logan, C.Y.; Lee, J.Y.; Honaker, R.W.; Cooper, R.L.; Passarelli, B.; Camorlinga, M.;
Bouley, D.M.; Alvarez, G.; et al. Helicobacter pylori activates and expands Lgr5(+) stem cells through direct
colonization of the gastric glands. Gastroenterology 2015, 148, 1392–1404. [CrossRef] [PubMed]
214. Wilhelm, F.; Simon, E.; Boger, C.; Behrens, H.M.; Kruger, S.; Rocken, C. Novel insights into gastric cancer:
Methylation of R-Spondins and regulation of LGR5 by SP1. Mol. Cancer Res. 2017, 15, 776–785. [CrossRef]
[PubMed]
215. Xi, H.Q.; Cui, J.X.; Shen, W.S.; Wu, X.S.; Bian, S.B.; Li, J.Y.; Song, Z.; Wei, B.; Chen, L. Increased expression
of Lgr5 is associated with chemotherapy resistance in human gastric cancer. Oncol. Rep. 2014, 32, 181–188.
[CrossRef] [PubMed]
216. Geng, Y.; Lu, X.; Wu, X.; Xue, L.; Wang, X.; Xu, J. MicroRNA-27b suppresses Helicobacter pylori-induced
gastric tumorigenesis through negatively regulating Frizzled7. Oncol. Rep. 2016, 35, 2441–2450. [CrossRef]
[PubMed]
217. Gnad, T.; Feoktistova, M.; Leverkus, M.; Lendeckel, U.; Naumann, M. Helicobacter pylori-induced activation
of β-catenin involves low density lipoprotein receptor-related protein 6 and Dishevelled. Mol. Cancer 2010,
9, 31. [CrossRef] [PubMed]
218. Flanagan, D.J.; Vincan, E.; Phesse, T.J. Winding back Wnt signalling: Potential therapeutic targets for treating
gastric cancers. Br. J. Pharmacol. 2017. [CrossRef] [PubMed]
Genes 2018, 9, 178 31 of 32
219. Wang, K.; Yuen, S.T.; Xu, J.; Lee, S.P.; Yan, H.H.; Shi, S.T.; Siu, H.C.; Deng, S.; Chu, K.M.; Law, S.; et al.
Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric
cancer. Nat. Genet. 2014, 46, 573–582. [CrossRef] [PubMed]
220. Min, B.H.; Hwang, J.; Kim, N.K.; Park, G.; Kang, S.Y.; Ahn, S.; Ahn, S.; Ha, S.Y.; Lee, Y.K.; Kushima, R.;
et al. Dysregulated Wnt signalling and recurrent mutations of the tumour suppressor RNF43 in early gastric
carcinogenesis. J. Pathol. 2016, 240, 304–314. [CrossRef] [PubMed]
221. Jiang, X.; Hao, H.X.; Growney, J.D.; Woolfenden, S.; Bottiglio, C.; Ng, N.; Lu, B.; Hsieh, M.H.;
Bagdasarian, L.; Meyer, R.; et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic
ductal adenocarcinoma. Proc. Natl. Acad. Sci. USA 2013, 110, 12649–12654. [CrossRef] [PubMed]
222. Steinhart, Z.; Pavlovic, Z.; Chandrashekhar, M.; Hart, T.; Wang, X.; Zhang, X.; Robitaille, M.; Brown, K.R.;
Jaksani, S.; Overmeer, R.; et al. Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as
a druggable vulnerability of RNF43-mutant pancreatic tumors. Nat. Med. 2017, 23, 60–68. [CrossRef]
[PubMed]
223. Cadigan, K.M.; Waterman, M.L. TCF/LEFs and Wnt signaling in the nucleus. Cold Spring Harb. Perspect. Biol.
2012, 4. [CrossRef] [PubMed]
224. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [CrossRef]
[PubMed]
225. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric
adenocarcinoma. Nature 2014, 513, 202–209. [CrossRef]
226. Li, J.; Woods, S.L.; Healey, S.; Beesley, J.; Chen, X.; Lee, J.S.; Sivakumaran, H.; Wayte, N.; Nones, K.;
Waterfall, J.J.; et al. Point mutations in exon 1B of APC reveal gastric adenocarcinoma and proximal
polyposis of the stomach as a familial adenomatous polyposis variant. Am. J. Hum. Genet. 2016, 98, 830–842.
[CrossRef] [PubMed]
227. Clements, W.M.; Wang, J.; Sarnaik, A.; Kim, O.J.; MacDonald, J.; Fenoglio-Preiser, C.; Groden, J.; Lowy, A.M.
beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res. 2002, 62,
3503–3506. [PubMed]
228. Woo, D.K.; Kim, H.S.; Lee, H.S.; Kang, Y.H.; Yang, H.K.; Kim, W.H. Altered expression and mutation of
beta-catenin gene in gastric carcinomas and cell lines. Int. J. Cancer 2001, 95, 108–113. [CrossRef]
229. Akama, Y.; Yasui, W.; Yokozaki, H.; Kuniyasu, H.; Kitahara, K.; Ishikawa, T.; Tahara, E. Frequent amplification
of the cyclin E gene in human gastric carcinomas. Jpn. J. Cancer Res. 1995, 86, 617–621. [CrossRef] [PubMed]
230. He, T. Identification of c-MYC as a target of the APC pathway. Science 1998, 281, 1509–1512. [CrossRef]
[PubMed]
231. Jiang, H.; Xia, J.; Kang, J.; Ding, Y.; Wu, W. Short hairpin RNA targeting beta-catenin suppresses cell
proliferation and induces apoptosis in human gastric carcinoma cells. Scand. J. Gastroenterol. 2009, 44,
1452–1462. [CrossRef] [PubMed]
232. Cheng, Y.Y.; Yu, J.; Wong, Y.P.; Man, E.P.; To, K.F.; Jin, V.X.; Li, J.; Tao, Q.; Sung, J.J.; Chan, F.K.; et al. Frequent
epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human
gastric cancer. Br. J. Cancer 2007, 97, 895–901. [CrossRef] [PubMed]
233. Nojima, M.; Suzuki, H.; Toyota, M.; Watanabe, Y.; Maruyama, R.; Sasaki, S.; Sasaki, Y.; Mita, H.; Nishikawa, N.;
Yamaguchi, K.; et al. Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt
signaling in gastric cancer. Oncogene 2007, 26, 4699–4713. [CrossRef] [PubMed]
234. Wang, B.; Liu, J.; Ma, L.N.; Xiao, H.L.; Wang, Y.Z.; Li, Y.; Wang, Z.; Fan, L.; Lan, C.; Yang, M.; et al. Chimeric
5/35 adenovirus-mediated Dickkopf-1 overexpression suppressed tumorigenicity of CD44(+) gastric cancer
cells via attenuating Wnt signaling. J. Gastroenterol. 2012. [CrossRef] [PubMed]
235. Moon, R.T. An introduction to non-canonical Wnt and Frizzled signaling. Semin. Cell Dev. Biol. 2002, 13, 215.
[CrossRef]
236. Kurayoshi, M.; Oue, N.; Yamamoto, H.; Kishida, M.; Inoue, A.; Asahara, T.; Yasui, W.; Kikuchi, A. Expression
of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion.
Cancer Res. 2006, 66, 10439–10448. [CrossRef] [PubMed]
237. Zhao, C.M.; Hayakawa, Y.; Kodama, Y.; Muthupalani, S.; Westphalen, C.B.; Andersen, G.T.; Flatberg, A.;
Johannessen, H.; Friedman, R.A.; Renz, B.W.; et al. Denervation suppresses gastric tumorigenesis.
Sci. Transl. Med. 2014, 6, 250ra115. [CrossRef] [PubMed]
Genes 2018, 9, 178 32 of 32
238. Kirikoshi, H.; Sekihara, H.; Katoh, M. Expression profiles of 10 members of Frizzled gene family in human
gastric cancer. Int. J. Oncol. 2001, 19, 767–771. [CrossRef] [PubMed]
239. Schmuck, R.; Warneke, V.; Behrens, H.M.; Simon, E.; Weichert, W.; Rocken, C. Genotypic and phenotypic
characterization of side population of gastric cancer cell lines. Am. J. Pathol. 2011, 178, 1792–1804. [CrossRef]
[PubMed]
240. Radulescu, S.; Ridgway, R.A.; Cordero, J.; Athineos, D.; Salgueiro, P.; Poulsom, R.; Neumann, J.; Jung, A.;
Patel, S.; Woodgett, J.; et al. Acute WNT signalling activation perturbs differentiation within the adult
stomach and rapidly leads to tumour formation. Oncogene 2012. [CrossRef] [PubMed]
241. Hayakawa, Y.; Sakitani, K.; Konishi, M.; Asfaha, S.; Niikura, R.; Tomita, H.; Renz, B.W.; Tailor, Y.; Macchini, M.;
Middelhoff, M.; et al. Nerve growth factor promotes gastric tumorigenesis through aberrant cholinergic
signaling. Cancer Cell 2017, 31, 21–34. [CrossRef] [PubMed]
242. Powell, A.E.; Vlacich, G.; Zhao, Z.Y.; McKinley, E.T.; Washington, M.K.; Manning, H.C.; Coffey, R.J. Inducible
loss of one Apc allele in Lrig1-expressing progenitor cells results in multiple distal colonic tumors with
features of familial adenomatous polyposis. Am. J. Physiol. Gastrointest. Liver Physiol. 2014, 307, G16–G23.
[CrossRef] [PubMed]
243. Phesse, T.J.; Sansom, O.J. Responding to R-Spondin: Slit2 potentiates intestinal regeneration. Cell Stem Cell
2013, 13, 512–514. [CrossRef] [PubMed]
244. Vincan, E.; Schwab, R.H.M.; Flanagan, D.J.; Moselen, J.M.; Tran, B.M.; Barker, N.; Phesse, T.J. The central role
of Wnt signaling and organoid technology in personalizing anticancer therapy. Prog. Mol. Biol. Transl. Sci.
2018, 153, 299–319. [CrossRef] [PubMed]
245. Phesse, T.J.; Durban, V.M.; Sansom, O.J. Defining key concepts of intestinal and epithelial cancer biology
through the use of mouse models. Carcinogenesis 2017, 38, 953–965. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
